Covered recipient · General Payments record
MUHAMMAD IRFAN
Allopathic & Osteopathic Physicians Internal Medicine
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2021 · Entire year
$1,222.37
56 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2021 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $1,009.42 | 50 |
| Education | $212.95 | 6 |
By paying entity
PY2021 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Novo Nordisk Inc | $226.04 | 8 |
| Amarin Pharma Inc. | $225.54 | 11 |
| Astellas Pharma US Inc | $184.99 | 2 |
| DEXCOM, INC. | $92.59 | 5 |
| AbbVie Inc. | $89.80 | 4 |
| Janssen Pharmaceuticals, Inc | $65.34 | 4 |
| Esperion Therapeutics, Inc. | $47.64 | 2 |
| Bayer HealthCare Pharmaceuticals Inc. | $46.73 | 3 |
| Abbott Laboratories | $45.96 | 3 |
| Radius Health, Inc. | $36.30 | 1 |
| Amgen Inc. | $30.08 | 2 |
| AstraZeneca Pharmaceuticals LP | $28.58 | 2 |
| Sunovion Pharmaceuticals Inc. | $21.93 | 2 |
| Xeris Pharmaceuticals, Inc. | $21.92 | 1 |
| Mylan Specialty L.P. | $20.53 | 1 |
| PFIZER INC. | $14.07 | 3 |
| Merck Sharp & Dohme Corporation | $12.32 | 1 |
| Genentech USA, Inc. | $12.01 | 1 |
Page 2 of 2; records 51–56 of 56 matching records. This page contains 6 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
MUHAMMAD IRFAN
NPI 1972570489 · CMS profile ID 44336
Allopathic & Osteopathic Physicians / Internal Medicine
TOMBALL, TX
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 2 of 2; records 51–56 of 56 matching records. This page contains 6 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1972570489?year=2021&recipient=provider&page=2#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- MUHAMMAD IRFAN, NPI 1972570489, CMS profile ID 44336. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–56 of 56 matching records. This page contains 6 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1972570489?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
- APA 7
- IndustryPayments. (2026). MUHAMMAD IRFAN, NPI 1972570489, CMS profile ID 44336. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–56 of 56 matching records. This page contains 6 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1972570489?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
- Bluebook
- MUHAMMAD IRFAN, NPI 1972570489, CMS profile ID 44336, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–56 of 56 matching records. This page contains 6 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1972570489?year=2021&recipient=provider&page=2#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2021
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30
56 matching records · $1,222.37 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 51–56 of 56.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Amarin Pharma Inc. | $17.54 | 02/24/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 815279237 | CMS |
| DEXCOM, INC. | $20.19 | 02/02/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 845282019 | CMS |
| AbbVie Inc. | $14.18 | 01/27/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 794917507 | CMS |
| Amgen Inc. | $13.89 | 01/25/2021 | Education | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 826536751 | CMS |
| Abbott Laboratories | $18.97 | 01/18/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 818396987 | CMS |
| Genentech USA, Inc. | $12.01 | 01/15/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 835955345 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Recipient | $1,820.77 | 9 |
| PY2025 | Principal investigator | $4,586,682.38 | 621 |
| PY2024 | Principal investigator | $5,884,888.71 | 693 |
| PY2023 | Recipient | $47,520.72 | 7 |
| PY2023 | Principal investigator | $10,339,998.16 | 3,722 |
| PY2022 | Recipient | $1,324.00 | 1 |
| PY2022 | Principal investigator | $7,282,013.18 | 1,802 |
| PY2021 | Principal investigator | $1,711,300.83 | 201 |
| PY2020 | Principal investigator | $376,584.96 | 63 |
| PY2019 | Principal investigator | $438,128.06 | 83 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
630 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | PFIZER INC. | $55,096.95 | 12/31/2025 | Non-covered Recipient Entity Dynamed Clinical Research LP | A PHASE 12 RANDOMIZED DOUBLEBLIND TRIAL OF THE SAFETY AND IMMUNOGENICITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE IN ADULTS 18 YEARS OF AGE AND OLDER | No dispute reported | 06/30/2026 | 1228806349 |
| Principal investigator 1 | ModernaTX, Inc. | $320.65 | 12/29/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants | No dispute reported | 06/30/2026 | 1252992544 |
| Principal investigator 1 | ModernaTX, Inc. | $245.13 | 12/29/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants | No dispute reported | 06/30/2026 | 1252992676 |
| Principal investigator 1 | ModernaTX, Inc. | $209.35 | 12/29/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants | No dispute reported | 06/30/2026 | 1252992678 |
| Principal investigator 1 | ModernaTX, Inc. | $99.38 | 12/29/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants | No dispute reported | 06/30/2026 | 1252992680 |
| Principal investigator 1 | ModernaTX, Inc. | $265.00 | 12/29/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants | No dispute reported | 06/30/2026 | 1252992690 |
| Principal investigator 1 | PFIZER INC. | $8,546.28 | 12/23/2025 | Non-covered Recipient Entity Dynamed Clinical Research LP | A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1228816912 |
| Principal investigator 1 | ModernaTX, Inc. | $2,351.85 | 12/19/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants | No dispute reported | 06/30/2026 | 1252992412 |
| Principal investigator 1 | ModernaTX, Inc. | $1,772.82 | 12/19/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants | No dispute reported | 06/30/2026 | 1252992416 |
| Principal investigator 1 | ModernaTX, Inc. | $166.14 | 12/19/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants | No dispute reported | 06/30/2026 | 1252992420 |
| Principal investigator 1 | ModernaTX, Inc. | $6,889.88 | 12/19/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants | No dispute reported | 06/30/2026 | 1252992422 |
| Principal investigator 1 | ModernaTX, Inc. | $368.00 | 12/19/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants | No dispute reported | 06/30/2026 | 1252992428 |
| Principal investigator 1 | ModernaTX, Inc. | $483.86 | 12/19/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants | No dispute reported | 06/30/2026 | 1252992538 |
| Principal investigator 1 | ModernaTX, Inc. | $83.10 | 12/19/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants | No dispute reported | 06/30/2026 | 1252992572 |
| Principal investigator 1 | ModernaTX, Inc. | $100.00 | 12/19/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants | No dispute reported | 06/30/2026 | 1252992816 |
| Principal investigator 1 | ModernaTX, Inc. | $3,012.00 | 12/19/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants | No dispute reported | 06/30/2026 | 1252992818 |
| Principal investigator 1 | ModernaTX, Inc. | $198.75 | 12/19/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants | No dispute reported | 06/30/2026 | 1252992834 |
| Principal investigator 1 | ModernaTX, Inc. | $100.00 | 12/17/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants | No dispute reported | 06/30/2026 | 1252992404 |
| Principal investigator 1 | ModernaTX, Inc. | $90.63 | 12/17/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants | No dispute reported | 06/30/2026 | 1252992568 |
| Principal investigator 1 | ModernaTX, Inc. | $95.40 | 12/17/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants | No dispute reported | 06/30/2026 | 1252992694 |
| Principal investigator 1 | ModernaTX, Inc. | $12,023.61 | 12/17/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Study of mRNA-1647 Cytomegalovirus Vaccine in Healthy Participants 9 to 15 Years of Age and Participants 16 to 25 Years of Age | No dispute reported | 06/30/2026 | 1252992776 |
| Principal investigator 1 | ModernaTX, Inc. | $364.38 | 12/17/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants | No dispute reported | 06/30/2026 | 1252992810 |
| Principal investigator 1 | ModernaTX, Inc. | $11,631.04 | 12/17/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Study to Investigate the Immunogenicity and Safety of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in High-risk Adults | No dispute reported | 06/30/2026 | 1252992852 |
| Principal investigator 1 | PFIZER INC. | $53,768.00 | 12/17/2025 | Non-covered Recipient Entity Dynamed Clinical Research LP | A PHASE 3 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BNT162B2 RNABASED VARIANTADAPTED VACCINE CANDIDATES AGAINST SARSCOV2 IN PARTICIPANTS 12 THROUGH 64 YEARS OF AGE CONSIDERED AT HIGHER RISK OF SEVERE COVID19 AND PARTICIPANTS 65 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228707800 |
| Principal investigator 1 | PFIZER INC. | $25,733.39 | 12/17/2025 | Non-covered Recipient Entity Dynamed Clinical Research LP | A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1228816635 |
| Principal investigator 1 | PFIZER INC. | $59,823.96 | 12/16/2025 | Non-covered Recipient Entity Dynamed Clinical Research LP | A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1228816972 |
| Principal investigator 1 | ModernaTX, Inc. | $626.00 | 12/15/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 | No dispute reported | 06/30/2026 | 1252992454 |
| Principal investigator 1 | ModernaTX, Inc. | $4,000.00 | 12/15/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 | No dispute reported | 06/30/2026 | 1252992600 |
| Principal investigator 1 | ModernaTX, Inc. | $2,000.00 | 12/15/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253009760 |
| Principal investigator 1 | Bavarian Nordic A/S | $483.63 | 12/12/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | EBSI-CV-317-008 | No dispute reported | 06/30/2026 | 1250214142 |
| Principal investigator 1 | Bavarian Nordic A/S | $430.63 | 12/12/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | EBSI-CV-317-008 | No dispute reported | 06/30/2026 | 1250214148 |
| Principal investigator 1 | Bavarian Nordic A/S | $483.63 | 12/12/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | EBSI-CV-317-008 | No dispute reported | 06/30/2026 | 1250214252 |
| Principal investigator 1 | ModernaTX, Inc. | $4,642.87 | 12/12/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Study to Investigate the Immunogenicity and Safety of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in High-risk Adults | No dispute reported | 06/30/2026 | 1252992470 |
| Principal investigator 1 | ModernaTX, Inc. | $377.63 | 12/12/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Study to Investigate the Immunogenicity and Safety of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in High-risk Adults | No dispute reported | 06/30/2026 | 1252992606 |
| Principal investigator 1 | ModernaTX, Inc. | $159.00 | 12/12/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Study to Investigate the Immunogenicity and Safety of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in High-risk Adults | No dispute reported | 06/30/2026 | 1252992620 |
| Principal investigator 1 | ModernaTX, Inc. | $20,822.00 | 12/12/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Study to Investigate the Immunogenicity and Safety of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in High-risk Adults | No dispute reported | 06/30/2026 | 1252992622 |
| Principal investigator 1 | ModernaTX, Inc. | $2,196.88 | 12/12/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Study to Investigate the Immunogenicity and Safety of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in High-risk Adults | No dispute reported | 06/30/2026 | 1252992628 |
| Principal investigator 1 | ModernaTX, Inc. | $10,272.00 | 12/12/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Study to Investigate the Immunogenicity and Safety of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in High-risk Adults | No dispute reported | 06/30/2026 | 1252992742 |
| Principal investigator 1 | ModernaTX, Inc. | $271.64 | 12/12/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Study to Investigate the Immunogenicity and Safety of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in High-risk Adults | No dispute reported | 06/30/2026 | 1252992746 |
| Principal investigator 1 | ModernaTX, Inc. | $17,563.00 | 12/12/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Study to Investigate the Immunogenicity and Safety of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in High-risk Adults | No dispute reported | 06/30/2026 | 1252992754 |
| Principal investigator 1 | ModernaTX, Inc. | $106.00 | 12/12/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Study to Investigate the Immunogenicity and Safety of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in High-risk Adults | No dispute reported | 06/30/2026 | 1252992756 |
| Principal investigator 1 | ModernaTX, Inc. | $152.38 | 12/12/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Study to Investigate the Immunogenicity and Safety of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in High-risk Adults | No dispute reported | 06/30/2026 | 1252992764 |
| Principal investigator 1 | ModernaTX, Inc. | $2,438.00 | 12/12/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Study to Investigate the Immunogenicity and Safety of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in High-risk Adults | No dispute reported | 06/30/2026 | 1252992766 |
| Principal investigator 1 | ModernaTX, Inc. | $2,475.14 | 12/12/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Study to Investigate the Immunogenicity and Safety of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in High-risk Adults | No dispute reported | 06/30/2026 | 1252992840 |
| Principal investigator 1 | ModernaTX, Inc. | $3,258.50 | 12/12/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Study to Investigate the Immunogenicity and Safety of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in High-risk Adults | No dispute reported | 06/30/2026 | 1252992844 |
| Principal investigator 1 | ModernaTX, Inc. | $92.75 | 12/12/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Study to Investigate the Immunogenicity and Safety of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in High-risk Adults | No dispute reported | 06/30/2026 | 1252992856 |
| Principal investigator 1 | Novavax Inc | $630.00 | 12/12/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Phase 3, open-label, single arm study to evaluate the safety and immunogenicity of a single dose of an Omicron JN. | No dispute reported | 06/30/2026 | 1242918935 |
| Principal investigator 1 | Novavax Inc | $86,024.69 | 12/12/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Phase 3, open-label, single arm study to evaluate the safety and immunogenicity of a single dose of an Omicron JN. | No dispute reported | 06/30/2026 | 1242919692 |
| Principal investigator 1 | Novavax Inc | $560.00 | 12/12/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Phase 3, open-label, single arm study to evaluate the safety and immunogenicity of a single dose of an Omicron JN. | No dispute reported | 06/30/2026 | 1242919696 |
| Principal investigator 1 | Novavax Inc | $251,795.16 | 12/12/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Phase 3, open-label, single arm study to evaluate the safety and immunogenicity of a single dose of an Omicron JN. | No dispute reported | 06/30/2026 | 1242920170 |
| Principal investigator 1 | Novavax Inc | $5,800.00 | 12/12/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Phase 3, open-label, single arm study to evaluate the safety and immunogenicity of a single dose of an Omicron JN. | No dispute reported | 06/30/2026 | 1242921038 |
| Principal investigator 1 | PFIZER INC. | $20,350.00 | 12/12/2025 | Non-covered Recipient Entity Dynamed Clinical Research LP | A PHASE 3 PLACEBOCONTROLLED DOUBLEBLINDED RANDOMIZED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIOIDES DIFFICILE VACCINE IN ADULTS 65 YEARS OF AGE AND OLDER | No dispute reported | 06/30/2026 | 1228806411 |
| Principal investigator 1 | ModernaTX, Inc. | $1,060.00 | 12/10/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Study to Investigate the Immunogenicity and Safety of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in High-risk Adults | No dispute reported | 06/30/2026 | 1252992478 |
| Principal investigator 1 | ModernaTX, Inc. | $9,335.00 | 12/10/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Study to Investigate the Immunogenicity and Safety of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in High-risk Adults | No dispute reported | 06/30/2026 | 1252992770 |
| Principal investigator 1 | PFIZER INC. | $57.20 | 12/06/2025 | Non-covered Recipient Entity Dynamed Clinical Research LP dba DM Clinical Research | A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND TOLERABILITY OF RIMEGEPANT FOR THE PREVENTION OF MIGRAINE IN ADULTS WITH A HISTORY OF INADEQUATE RESPONSE TO ORAL PREVENTIVE MEDICATIONS | No dispute reported | 06/30/2026 | 1228704450 |
| Principal investigator 1 | PFIZER INC. | $13.00 | 12/06/2025 | Non-covered Recipient Entity Dynamed Clinical Research LP dba DM Clinical Research | A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE | No dispute reported | 06/30/2026 | 1228704550 |
| Principal investigator 1 | PFIZER INC. | $167.03 | 12/06/2025 | Non-covered Recipient Entity Dynamed Clinical Research LP dba DM Clinical Research | A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND TOLERABILITY OF RIMEGEPANT FOR THE PREVENTION OF MIGRAINE IN ADULTS WITH A HISTORY OF INADEQUATE RESPONSE TO ORAL PREVENTIVE MEDICATIONS | No dispute reported | 06/30/2026 | 1228704552 |
| Principal investigator 1 | PFIZER INC. | $41.75 | 12/06/2025 | Non-covered Recipient Entity Dynamed Clinical Research LP dba DM Clinical Research | A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE | No dispute reported | 06/30/2026 | 1228704554 |
| Principal investigator 1 | PFIZER INC. | $68.13 | 12/06/2025 | Non-covered Recipient Entity Dynamed Clinical Research LP dba DM Clinical Research | A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND TOLERABILITY OF RIMEGEPANT FOR THE PREVENTION OF MIGRAINE IN ADULTS WITH A HISTORY OF INADEQUATE RESPONSE TO ORAL PREVENTIVE MEDICATIONS | No dispute reported | 06/30/2026 | 1228704626 |
| Principal investigator 1 | PFIZER INC. | $41.75 | 12/06/2025 | Non-covered Recipient Entity Dynamed Clinical Research LP dba DM Clinical Research | A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE | No dispute reported | 06/30/2026 | 1228704628 |
| Principal investigator 1 | PFIZER INC. | $8.00 | 12/06/2025 | Non-covered Recipient Entity Dynamed Clinical Research LP dba DM Clinical Research | A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE | No dispute reported | 06/30/2026 | 1228704672 |
| Principal investigator 1 | PFIZER INC. | $77.07 | 12/06/2025 | Non-covered Recipient Entity Dynamed Clinical Research LP dba DM Clinical Research | A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE | No dispute reported | 06/30/2026 | 1228704674 |
| Principal investigator 1 | PFIZER INC. | $68.46 | 12/06/2025 | Non-covered Recipient Entity Dynamed Clinical Research LP dba DM Clinical Research | A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE | No dispute reported | 06/30/2026 | 1228704676 |
| Principal investigator 1 | PFIZER INC. | $77.07 | 12/06/2025 | Non-covered Recipient Entity Dynamed Clinical Research LP dba DM Clinical Research | A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE | No dispute reported | 06/30/2026 | 1228704678 |
| Principal investigator 1 | PFIZER INC. | $68.46 | 12/06/2025 | Non-covered Recipient Entity Dynamed Clinical Research LP dba DM Clinical Research | A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE | No dispute reported | 06/30/2026 | 1228704680 |
| Principal investigator 1 | PFIZER INC. | $95.96 | 12/06/2025 | Non-covered Recipient Entity Dynamed Clinical Research LP dba DM Clinical Research | A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE | No dispute reported | 06/30/2026 | 1228704682 |
| Principal investigator 1 | PFIZER INC. | $8.00 | 12/06/2025 | Non-covered Recipient Entity Dynamed Clinical Research LP dba DM Clinical Research | A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE | No dispute reported | 06/30/2026 | 1228704736 |
| Principal investigator 1 | PFIZER INC. | $13.00 | 12/06/2025 | Non-covered Recipient Entity Dynamed Clinical Research LP dba DM Clinical Research | A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE | No dispute reported | 06/30/2026 | 1228704738 |
| Principal investigator 1 | PFIZER INC. | $90.66 | 12/06/2025 | Non-covered Recipient Entity Dynamed Clinical Research LP dba DM Clinical Research | A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE | No dispute reported | 06/30/2026 | 1228704740 |
| Principal investigator 1 | PFIZER INC. | $81.51 | 12/06/2025 | Non-covered Recipient Entity Dynamed Clinical Research LP dba DM Clinical Research | A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE | No dispute reported | 06/30/2026 | 1228704742 |
| Principal investigator 1 | PFIZER INC. | $77.07 | 12/06/2025 | Non-covered Recipient Entity Dynamed Clinical Research LP dba DM Clinical Research | A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE | No dispute reported | 06/30/2026 | 1228704820 |
| Principal investigator 1 | PFIZER INC. | $80.06 | 12/06/2025 | Non-covered Recipient Entity Dynamed Clinical Research LP dba DM Clinical Research | A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE | No dispute reported | 06/30/2026 | 1228704822 |
| Principal investigator 1 | PFIZER INC. | $96.95 | 12/06/2025 | Non-covered Recipient Entity Dynamed Clinical Research LP dba DM Clinical Research | A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND TOLERABILITY OF RIMEGEPANT FOR THE PREVENTION OF MIGRAINE IN ADULTS WITH A HISTORY OF INADEQUATE RESPONSE TO ORAL PREVENTIVE MEDICATIONS | No dispute reported | 06/30/2026 | 1228704824 |
| Principal investigator 1 | PFIZER INC. | $8.00 | 12/06/2025 | Non-covered Recipient Entity Dynamed Clinical Research LP dba DM Clinical Research | A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE | No dispute reported | 06/30/2026 | 1228704872 |
| Principal investigator 1 | PFIZER INC. | $13.00 | 12/06/2025 | Non-covered Recipient Entity Dynamed Clinical Research LP dba DM Clinical Research | A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE | No dispute reported | 06/30/2026 | 1228704874 |
| Principal investigator 1 | PFIZER INC. | $90.66 | 12/06/2025 | Non-covered Recipient Entity Dynamed Clinical Research LP dba DM Clinical Research | A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE | No dispute reported | 06/30/2026 | 1228704920 |
| Principal investigator 1 | PFIZER INC. | $76.41 | 12/06/2025 | Non-covered Recipient Entity Dynamed Clinical Research LP dba DM Clinical Research | A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND TOLERABILITY OF RIMEGEPANT FOR THE PREVENTION OF MIGRAINE IN ADULTS WITH A HISTORY OF INADEQUATE RESPONSE TO ORAL PREVENTIVE MEDICATIONS | No dispute reported | 06/30/2026 | 1228704922 |
| Principal investigator 1 | PFIZER INC. | $8.00 | 12/06/2025 | Non-covered Recipient Entity Dynamed Clinical Research LP dba DM Clinical Research | A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE | No dispute reported | 06/30/2026 | 1228704924 |
| Principal investigator 1 | PFIZER INC. | $95.96 | 12/06/2025 | Non-covered Recipient Entity Dynamed Clinical Research LP dba DM Clinical Research | A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE | No dispute reported | 06/30/2026 | 1228704980 |
| Principal investigator 1 | PFIZER INC. | $81.51 | 12/06/2025 | Non-covered Recipient Entity Dynamed Clinical Research LP dba DM Clinical Research | A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE | No dispute reported | 06/30/2026 | 1228705022 |
| Principal investigator 1 | PFIZER INC. | $110.33 | 12/06/2025 | Non-covered Recipient Entity Dynamed Clinical Research LP dba DM Clinical Research | A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE | No dispute reported | 06/30/2026 | 1228705046 |
| Principal investigator 1 | PFIZER INC. | $95.96 | 12/06/2025 | Non-covered Recipient Entity Dynamed Clinical Research LP dba DM Clinical Research | A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE | No dispute reported | 06/30/2026 | 1228705048 |
| Principal investigator 1 | PFIZER INC. | $99.27 | 12/06/2025 | Non-covered Recipient Entity Dynamed Clinical Research LP dba DM Clinical Research | A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND TOLERABILITY OF RIMEGEPANT FOR THE PREVENTION OF MIGRAINE IN ADULTS WITH A HISTORY OF INADEQUATE RESPONSE TO ORAL PREVENTIVE MEDICATIONS | No dispute reported | 06/30/2026 | 1228705110 |
| Principal investigator 1 | PFIZER INC. | $81.51 | 12/06/2025 | Non-covered Recipient Entity Dynamed Clinical Research LP dba DM Clinical Research | A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE | No dispute reported | 06/30/2026 | 1228705112 |
| Principal investigator 1 | PFIZER INC. | $110.33 | 12/06/2025 | Non-covered Recipient Entity Dynamed Clinical Research LP dba DM Clinical Research | A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE | No dispute reported | 06/30/2026 | 1228705168 |
| Principal investigator 1 | PFIZER INC. | $120.93 | 12/06/2025 | Non-covered Recipient Entity Dynamed Clinical Research LP dba DM Clinical Research | A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND TOLERABILITY OF RIMEGEPANT FOR THE PREVENTION OF MIGRAINE IN ADULTS WITH A HISTORY OF INADEQUATE RESPONSE TO ORAL PREVENTIVE MEDICATIONS | No dispute reported | 06/30/2026 | 1228705216 |
| Principal investigator 1 | PFIZER INC. | $99.73 | 12/06/2025 | Non-covered Recipient Entity Dynamed Clinical Research LP dba DM Clinical Research | A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE | No dispute reported | 06/30/2026 | 1228705218 |
| Principal investigator 1 | PFIZER INC. | $90.66 | 12/06/2025 | Non-covered Recipient Entity Dynamed Clinical Research LP dba DM Clinical Research | A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE | No dispute reported | 06/30/2026 | 1228705220 |
| Principal investigator 1 | PFIZER INC. | $90.66 | 12/06/2025 | Non-covered Recipient Entity Dynamed Clinical Research LP dba DM Clinical Research | A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE | No dispute reported | 06/30/2026 | 1228705232 |
| Principal investigator 1 | PFIZER INC. | $109.79 | 12/06/2025 | Non-covered Recipient Entity Dynamed Clinical Research LP dba DM Clinical Research | A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE | No dispute reported | 06/30/2026 | 1228705334 |
| Principal investigator 1 | PFIZER INC. | $81.51 | 12/06/2025 | Non-covered Recipient Entity Dynamed Clinical Research LP dba DM Clinical Research | A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE | No dispute reported | 06/30/2026 | 1228705336 |
| Principal investigator 1 | PFIZER INC. | $110.33 | 12/06/2025 | Non-covered Recipient Entity Dynamed Clinical Research LP dba DM Clinical Research | A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE | No dispute reported | 06/30/2026 | 1228705352 |
| Principal investigator 1 | PFIZER INC. | $80.06 | 12/06/2025 | Non-covered Recipient Entity Dynamed Clinical Research LP dba DM Clinical Research | A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE | No dispute reported | 06/30/2026 | 1228705354 |
| Principal investigator 1 | PFIZER INC. | $96.62 | 12/06/2025 | Non-covered Recipient Entity Dynamed Clinical Research LP dba DM Clinical Research | A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND TOLERABILITY OF RIMEGEPANT FOR THE PREVENTION OF MIGRAINE IN ADULTS WITH A HISTORY OF INADEQUATE RESPONSE TO ORAL PREVENTIVE MEDICATIONS | No dispute reported | 06/30/2026 | 1228705406 |
| Principal investigator 1 | PFIZER INC. | $13.00 | 12/06/2025 | Non-covered Recipient Entity Dynamed Clinical Research LP dba DM Clinical Research | A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE | No dispute reported | 06/30/2026 | 1228705408 |
| Principal investigator 1 | PFIZER INC. | $68.46 | 12/06/2025 | Non-covered Recipient Entity Dynamed Clinical Research LP dba DM Clinical Research | A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE | No dispute reported | 06/30/2026 | 1228705410 |
| Principal investigator 1 | PFIZER INC. | $80.06 | 12/06/2025 | Non-covered Recipient Entity Dynamed Clinical Research LP dba DM Clinical Research | A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE | No dispute reported | 06/30/2026 | 1228705534 |
| Principal investigator 1 | PFIZER INC. | $88.00 | 12/06/2025 | Non-covered Recipient Entity Dynamed Clinical Research LP dba DM Clinical Research | A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND TOLERABILITY OF RIMEGEPANT FOR THE PREVENTION OF MIGRAINE IN ADULTS WITH A HISTORY OF INADEQUATE RESPONSE TO ORAL PREVENTIVE MEDICATIONS | No dispute reported | 06/30/2026 | 1228705536 |
| Principal investigator 1 | PFIZER INC. | $41.75 | 12/06/2025 | Non-covered Recipient Entity Dynamed Clinical Research LP dba DM Clinical Research | A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE | No dispute reported | 06/30/2026 | 1228705538 |
| Principal investigator 1 | Bavarian Nordic A/S | $231.88 | 12/05/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | EBSI-CV-317-008 | No dispute reported | 06/30/2026 | 1250214144 |
| Principal investigator 1 | Bavarian Nordic A/S | $475.86 | 12/05/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | EBSI-CV-317-008 | No dispute reported | 06/30/2026 | 1250214150 |
| Principal investigator 1 | Bavarian Nordic A/S | $430.63 | 12/05/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | EBSI-CV-317-008 | No dispute reported | 06/30/2026 | 1250214154 |
| Principal investigator 1 | Bavarian Nordic A/S | $470.38 | 12/05/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | EBSI-CV-317-008 | No dispute reported | 06/30/2026 | 1250214156 |
| Principal investigator 1 | Bavarian Nordic A/S | $470.38 | 12/05/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | EBSI-CV-317-008 | No dispute reported | 06/30/2026 | 1250214250 |
| Principal investigator 1 | ABBVIE INC. | $409.50 | 12/04/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate | No dispute reported | 06/30/2026 | 1202527058 |
| Principal investigator 1 | ABBVIE INC. | $1,656.93 | 12/04/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate | No dispute reported | 06/30/2026 | 1202527262 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $28,777.00 | 12/03/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH | A Phase III, Randomised, Double-blind, Placebo-controlled, Parallel-group Study to Assess the Effect of AZD0780 on Major Adverse Cardiovascular Events in Patients with Established Atherosclerotic Cardiovascular Disease (ASCVD) or at High Risk for a First ASCVD Event | No dispute reported | 06/30/2026 | 1185538384 |
| Principal investigator 1 | ModernaTX, Inc. | $3,852.00 | 12/03/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Study to Investigate the Immunogenicity and Safety of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in High-risk Adults | No dispute reported | 06/30/2026 | 1252992480 |
| Principal investigator 1 | ModernaTX, Inc. | $2,665.92 | 12/03/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Study to Investigate the Immunogenicity and Safety of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in High-risk Adults | No dispute reported | 06/30/2026 | 1252992616 |
| Principal investigator 1 | ModernaTX, Inc. | $150.00 | 12/03/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Study of mRNA-1647 Cytomegalovirus Vaccine in Healthy Participants 9 to 15 Years of Age and Participants 16 to 25 Years of Age | No dispute reported | 06/30/2026 | 1252992636 |
| Principal investigator 1 | ModernaTX, Inc. | $3,241.02 | 12/03/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Study of mRNA-1647 Cytomegalovirus Vaccine in Healthy Participants 9 to 15 Years of Age and Participants 16 to 25 Years of Age | No dispute reported | 06/30/2026 | 1252992638 |
| Principal investigator 1 | ModernaTX, Inc. | $2,250.00 | 12/03/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Study of mRNA-1647 Cytomegalovirus Vaccine in Healthy Participants 9 to 15 Years of Age and Participants 16 to 25 Years of Age | No dispute reported | 06/30/2026 | 1252992648 |
| Principal investigator 1 | ModernaTX, Inc. | $720.00 | 12/03/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age | No dispute reported | 06/30/2026 | 1252992662 |
| Principal investigator 1 | ModernaTX, Inc. | $1,636.40 | 12/03/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Study to Investigate the Immunogenicity and Safety of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in High-risk Adults | No dispute reported | 06/30/2026 | 1252992848 |
| Principal investigator 1 | ModernaTX, Inc. | $12,840.00 | 12/03/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Study to Investigate the Immunogenicity and Safety of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in High-risk Adults | No dispute reported | 06/30/2026 | 1252992854 |
| Principal investigator 1 | ModernaTX, Inc. | $3,000.00 | 12/03/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age | No dispute reported | 06/30/2026 | 1252992868 |
| Principal investigator 1 | ModernaTX, Inc. | $397.50 | 12/01/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age | No dispute reported | 06/30/2026 | 1252992510 |
| Principal investigator 1 | Novavax Inc | $2,000.00 | 12/01/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Phase 3, open-label, single arm study to evaluate the safety and immunogenicity of a single dose of an Omicron JN. | No dispute reported | 06/30/2026 | 1242920173 |
| Principal investigator 1 | Novavax Inc | $500.00 | 12/01/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Phase 3, open-label, single arm study to evaluate the safety and immunogenicity of a single dose of an Omicron JN. | No dispute reported | 06/30/2026 | 1242921035 |
| Principal investigator 1 | Novavax Inc | $1,968.87 | 12/01/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Phase 3, open-label, single arm study to evaluate the safety and immunogenicity of a single dose of an Omicron JN. | No dispute reported | 06/30/2026 | 1242921042 |
| Principal investigator 1 | Novavax Inc | $10,900.00 | 12/01/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Phase 3, open-label, single arm study to evaluate the safety and immunogenicity of a single dose of an Omicron JN. | No dispute reported | 06/30/2026 | 1242921831 |
| Principal investigator 1 | ModernaTX, Inc. | $483.86 | 11/27/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants | No dispute reported | 06/30/2026 | 1252992414 |
| Principal investigator 1 | ModernaTX, Inc. | $83.10 | 11/27/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants | No dispute reported | 06/30/2026 | 1252992550 |
| Principal investigator 1 | ModernaTX, Inc. | $775.32 | 11/27/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants | No dispute reported | 06/30/2026 | 1252992564 |
| Principal investigator 1 | ModernaTX, Inc. | $9,407.40 | 11/27/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants | No dispute reported | 06/30/2026 | 1252992684 |
| Principal investigator 1 | ModernaTX, Inc. | $7,091.28 | 11/27/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants | No dispute reported | 06/30/2026 | 1252992714 |
| Principal investigator 1 | ModernaTX, Inc. | $1,722.47 | 11/27/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants | No dispute reported | 06/30/2026 | 1252992820 |
| Principal investigator 1 | ModernaTX, Inc. | $132.50 | 11/26/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants | No dispute reported | 06/30/2026 | 1252992418 |
| Principal investigator 1 | ModernaTX, Inc. | $38.43 | 11/26/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants | No dispute reported | 06/30/2026 | 1252992554 |
| Principal investigator 1 | ModernaTX, Inc. | $47.70 | 11/26/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants | No dispute reported | 06/30/2026 | 1252992698 |
| Principal investigator 1 | ModernaTX, Inc. | $64.93 | 11/26/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants | No dispute reported | 06/30/2026 | 1252992830 |
| Principal investigator 1 | PFIZER INC. | $15,205.41 | 11/26/2025 | Non-covered Recipient Entity Dynamed Clinical Research LP | A PHASE 3 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BNT162B2 RNABASED VARIANTADAPTED VACCINE CANDIDATES AGAINST SARSCOV2 IN PARTICIPANTS 12 THROUGH 64 YEARS OF AGE CONSIDERED AT HIGHER RISK OF SEVERE COVID19 AND PARTICIPANTS 65 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228707804 |
| Principal investigator 1 | PFIZER INC. | $39,232.07 | 11/26/2025 | Non-covered Recipient Entity Dynamed Clinical Research LP | A PHASE 12 RANDOMIZED DOUBLEBLIND TRIAL OF THE SAFETY AND IMMUNOGENICITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE IN ADULTS 18 YEARS OF AGE AND OLDER | No dispute reported | 06/30/2026 | 1228817940 |
| Principal investigator 1 | PFIZER INC. | $100.00 | 11/25/2025 | Non-covered Recipient Entity Dynamed Clinical Research LP | A PHASE 12 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1228817948 |
| Principal investigator 1 | ModernaTX, Inc. | $6,896.51 | 11/24/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 | No dispute reported | 06/30/2026 | 1252992444 |
| Principal investigator 1 | ModernaTX, Inc. | $7,342.74 | 11/24/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 | No dispute reported | 06/30/2026 | 1252992452 |
| Principal investigator 1 | ModernaTX, Inc. | $466.95 | 11/24/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 | No dispute reported | 06/30/2026 | 1252992458 |
| Principal investigator 1 | ModernaTX, Inc. | $3,340.38 | 11/24/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 | No dispute reported | 06/30/2026 | 1252992586 |
| Principal investigator 1 | ModernaTX, Inc. | $7,240.72 | 11/24/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 | No dispute reported | 06/30/2026 | 1252992588 |
| Principal investigator 1 | ModernaTX, Inc. | $1,228.80 | 11/24/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 | No dispute reported | 06/30/2026 | 1252992590 |
| Principal investigator 1 | ModernaTX, Inc. | $2,349.27 | 11/24/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 | No dispute reported | 06/30/2026 | 1252992592 |
| Principal investigator 1 | ModernaTX, Inc. | $2,791.20 | 11/24/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 | No dispute reported | 06/30/2026 | 1252992594 |
| Principal investigator 1 | ModernaTX, Inc. | $3,841.49 | 11/24/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 | No dispute reported | 06/30/2026 | 1252992598 |
| Principal investigator 1 | ModernaTX, Inc. | $1,105.02 | 11/24/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 | No dispute reported | 06/30/2026 | 1252992602 |
| Principal investigator 1 | ModernaTX, Inc. | $2,789.80 | 11/24/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 | No dispute reported | 06/30/2026 | 1252992604 |
| Principal investigator 1 | ModernaTX, Inc. | $8,621.72 | 11/24/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 | No dispute reported | 06/30/2026 | 1252992726 |
| Principal investigator 1 | ModernaTX, Inc. | $4,342.52 | 11/24/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 | No dispute reported | 06/30/2026 | 1252992728 |
| Principal investigator 1 | ModernaTX, Inc. | $6,437.40 | 11/24/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 | No dispute reported | 06/30/2026 | 1252992736 |
| Principal investigator 1 | ModernaTX, Inc. | $4,141.54 | 11/24/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 | No dispute reported | 06/30/2026 | 1252992838 |
| Principal investigator 1 | ModernaTX, Inc. | $7,700.00 | 11/21/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Study to Investigate the Immunogenicity and Safety of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in High-risk Adults | No dispute reported | 06/30/2026 | 1252992472 |
| Principal investigator 1 | ModernaTX, Inc. | $2,000.00 | 11/21/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Study to Investigate the Immunogenicity and Safety of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in High-risk Adults | No dispute reported | 06/30/2026 | 1252992748 |
| Principal investigator 1 | ModernaTX, Inc. | $2,800.00 | 11/21/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Study to Investigate the Immunogenicity and Safety of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in High-risk Adults | No dispute reported | 06/30/2026 | 1252992752 |
| Principal investigator 1 | ModernaTX, Inc. | $997.72 | 11/21/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age | No dispute reported | 06/30/2026 | 1252992786 |
| Principal investigator 1 | Novavax Inc | $94.83 | 11/21/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Phase 3, open-label, single arm study to evaluate the safety and immunogenicity of a single dose of an Omicron JN. | No dispute reported | 06/30/2026 | 1242920595 |
| Principal investigator 1 | PFIZER INC. | $5,697.52 | 11/20/2025 | Non-covered Recipient Entity Dynamed Clinical Research LP | A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1228818382 |
| Principal investigator 1 | PFIZER INC. | $2,009.15 | 11/19/2025 | Non-covered Recipient Entity Dynamed Clinical Research LP | A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1228818900 |
| Principal investigator 1 | PFIZER INC. | $19,148.58 | 11/18/2025 | Non-covered Recipient Entity Dynamed Clinical Research LP | A PHASE 12 RANDOMIZED DOUBLEBLIND TRIAL OF THE SAFETY AND IMMUNOGENICITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE IN ADULTS 18 YEARS OF AGE AND OLDER | No dispute reported | 06/30/2026 | 1228817954 |
| Principal investigator 1 | PFIZER INC. | $9,970.66 | 11/15/2025 | Non-covered Recipient Entity Dynamed Clinical Research LP | A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1228818393 |
| Principal investigator 1 | PFIZER INC. | $32,551.90 | 11/13/2025 | Non-covered Recipient Entity Dynamed Clinical Research LP | A PHASE 3 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BNT162B2 RNABASED VARIANTADAPTED VACCINE CANDIDATES AGAINST SARSCOV2 IN PARTICIPANTS 12 THROUGH 64 YEARS OF AGE CONSIDERED AT HIGHER RISK OF SEVERE COVID19 AND PARTICIPANTS 65 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228707978 |
| Principal investigator 1 | Bavarian Nordic A/S | $470.38 | 11/12/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | EBSI-CV-317-008 | No dispute reported | 06/30/2026 | 1250214140 |
| Principal investigator 1 | Bavarian Nordic A/S | $613.70 | 11/12/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | EBSI-CV-317-008 | No dispute reported | 06/30/2026 | 1250214158 |
| Principal investigator 1 | Bavarian Nordic A/S | $4,566.88 | 11/12/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | EBSI-CV-317-008 | No dispute reported | 06/30/2026 | 1250214162 |
| Principal investigator 1 | PFIZER INC. | $19,941.32 | 11/11/2025 | Non-covered Recipient Entity Dynamed Clinical Research LP | A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1228818387 |
| Principal investigator 1 | ModernaTX, Inc. | $112.62 | 11/05/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age | No dispute reported | 06/30/2026 | 1252992652 |
| Principal investigator 1 | ModernaTX, Inc. | $1,199.91 | 11/05/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Clinical Study to Investigate the Safety and Immunogenicity in Relation to Product Attributes of mRNA-1083 (Severe Acute Respiratory Syndrome Coronavirus 2 [SARS-CoV-2] and Influenza Vaccine) | No dispute reported | 06/30/2026 | 1252992672 |
| Principal investigator 1 | PFIZER INC. | $123,266.08 | 11/05/2025 | Non-covered Recipient Entity Dynamed Clinical Research LP | A PHASE 3 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BNT162B2 RNABASED VARIANTADAPTED VACCINE CANDIDATES AGAINST SARSCOV2 IN PARTICIPANTS 12 THROUGH 64 YEARS OF AGE CONSIDERED AT HIGHER RISK OF SEVERE COVID19 AND PARTICIPANTS 65 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228707976 |
| Principal investigator 1 | PFIZER INC. | $11,500.00 | 11/04/2025 | Non-covered Recipient Entity Dynamed Clinical Research LP | A PHASE 3 STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS 60 YEARS OF AGE AND OLDER | No dispute reported | 06/30/2026 | 1228707802 |
| Principal investigator 1 | ModernaTX, Inc. | $11,222.85 | 11/03/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Study of mRNA-based Influenza and SARS-CoV-2 (COVID-19) Multi-component Vaccines in Healthy Adults | No dispute reported | 06/30/2026 | 1252992394 |
| Principal investigator 1 | PFIZER INC. | $2,848.76 | 10/30/2025 | Non-covered Recipient Entity Dynamed Clinical Research LP | A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1228825221 |
| Principal investigator 1 | ModernaTX, Inc. | $186.83 | 10/29/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Study of mRNA-1647 Cytomegalovirus Vaccine in Healthy Participants 9 to 15 Years of Age and Participants 16 to 25 Years of Age | No dispute reported | 06/30/2026 | 1252992492 |
| Principal investigator 1 | ModernaTX, Inc. | $7,526.00 | 10/29/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Study of mRNA-1647 Cytomegalovirus Vaccine in Healthy Participants 9 to 15 Years of Age and Participants 16 to 25 Years of Age | No dispute reported | 06/30/2026 | 1252992498 |
| Principal investigator 1 | ModernaTX, Inc. | $466.00 | 10/29/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Study of mRNA-1647 Cytomegalovirus Vaccine in Healthy Participants 9 to 15 Years of Age and Participants 16 to 25 Years of Age | No dispute reported | 06/30/2026 | 1252992500 |
| Principal investigator 1 | ModernaTX, Inc. | $466.00 | 10/29/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Study of mRNA-1647 Cytomegalovirus Vaccine in Healthy Participants 9 to 15 Years of Age and Participants 16 to 25 Years of Age | No dispute reported | 06/30/2026 | 1252992778 |
| Principal investigator 1 | ModernaTX, Inc. | $443.88 | 10/29/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Study of mRNA-1647 Cytomegalovirus Vaccine in Healthy Participants 9 to 15 Years of Age and Participants 16 to 25 Years of Age | No dispute reported | 06/30/2026 | 1252992780 |
| Principal investigator 1 | ModernaTX, Inc. | $440.00 | 10/29/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Study of mRNA-1647 Cytomegalovirus Vaccine in Healthy Participants 9 to 15 Years of Age and Participants 16 to 25 Years of Age | No dispute reported | 06/30/2026 | 1252992858 |
| Principal investigator 1 | ModernaTX, Inc. | $315.58 | 10/27/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants | No dispute reported | 06/30/2026 | 1252992570 |
| Principal investigator 1 | ModernaTX, Inc. | $1,451.58 | 10/27/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants | No dispute reported | 06/30/2026 | 1252992712 |
| Principal investigator 1 | ModernaTX, Inc. | $69.25 | 10/27/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants | No dispute reported | 06/30/2026 | 1252992826 |
| Principal investigator 1 | PFIZER INC. | $87,407.34 | 10/25/2025 | Non-covered Recipient Entity Dynamed Clinical Research LP | A PHASE 12 RANDOMIZED DOUBLEBLIND TRIAL OF THE SAFETY AND IMMUNOGENICITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE IN ADULTS 18 YEARS OF AGE AND OLDER | No dispute reported | 06/30/2026 | 1228823555 |
| Principal investigator 1 | Bavarian Nordic A/S | $231.88 | 10/24/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | EBSI-CV-317-008 | No dispute reported | 06/30/2026 | 1250214146 |
| Principal investigator 1 | ModernaTX, Inc. | $10,669.12 | 10/24/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Study to Investigate the Immunogenicity and Safety of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in High-risk Adults | No dispute reported | 06/30/2026 | 1252992618 |
| Principal investigator 1 | ModernaTX, Inc. | $932.00 | 10/24/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Study of mRNA-1647 Cytomegalovirus Vaccine in Healthy Participants 9 to 15 Years of Age and Participants 16 to 25 Years of Age | No dispute reported | 06/30/2026 | 1252992644 |
| Principal investigator 1 | ModernaTX, Inc. | $79.50 | 10/24/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Study of mRNA-1647 Cytomegalovirus Vaccine in Healthy Participants 9 to 15 Years of Age and Participants 16 to 25 Years of Age | No dispute reported | 06/30/2026 | 1252992646 |
| Principal investigator 1 | ModernaTX, Inc. | $1,187.20 | 10/24/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Study of mRNA-1647 Cytomegalovirus Vaccine in Healthy Participants 9 to 15 Years of Age and Participants 16 to 25 Years of Age | No dispute reported | 06/30/2026 | 1252992864 |
| Principal investigator 1 | ModernaTX, Inc. | $76.86 | 10/23/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants | No dispute reported | 06/30/2026 | 1252992406 |
| Principal investigator 1 | ModernaTX, Inc. | $92.00 | 10/23/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants | No dispute reported | 06/30/2026 | 1252992532 |
| Principal investigator 1 | ModernaTX, Inc. | $753.00 | 10/23/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants | No dispute reported | 06/30/2026 | 1252992576 |
| Principal investigator 1 | ModernaTX, Inc. | $129.86 | 10/23/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants | No dispute reported | 06/30/2026 | 1252992716 |
| Principal investigator 1 | PFIZER INC. | $2,418.63 | 10/23/2025 | Non-covered Recipient Entity Dynamed Clinical Research LP dba DM Clinical Research | A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND TOLERABILITY OF RIMEGEPANT FOR THE PREVENTION OF MIGRAINE IN ADULTS WITH A HISTORY OF INADEQUATE RESPONSE TO ORAL PREVENTIVE MEDICATIONS | No dispute reported | 06/30/2026 | 1228704452 |
| Principal investigator 1 | PFIZER INC. | $2,206.63 | 10/23/2025 | Non-covered Recipient Entity Dynamed Clinical Research LP dba DM Clinical Research | A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE | No dispute reported | 06/30/2026 | 1228704876 |
| Principal investigator 1 | PFIZER INC. | $2,206.63 | 10/23/2025 | Non-covered Recipient Entity Dynamed Clinical Research LP dba DM Clinical Research | A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE | No dispute reported | 06/30/2026 | 1228705050 |
| Principal investigator 1 | PFIZER INC. | $2,418.63 | 10/23/2025 | Non-covered Recipient Entity Dynamed Clinical Research LP dba DM Clinical Research | A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND TOLERABILITY OF RIMEGEPANT FOR THE PREVENTION OF MIGRAINE IN ADULTS WITH A HISTORY OF INADEQUATE RESPONSE TO ORAL PREVENTIVE MEDICATIONS | No dispute reported | 06/30/2026 | 1228705114 |
| Principal investigator 1 | PFIZER INC. | $1,073.75 | 10/23/2025 | Non-covered Recipient Entity Dynamed Clinical Research LP dba DM Clinical Research | A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND TOLERABILITY OF RIMEGEPANT FOR THE PREVENTION OF MIGRAINE IN ADULTS WITH A HISTORY OF INADEQUATE RESPONSE TO ORAL PREVENTIVE MEDICATIONS | No dispute reported | 06/30/2026 | 1228705350 |
| Principal investigator 1 | ModernaTX, Inc. | $6,244.53 | 10/22/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Study to Investigate the Immunogenicity and Safety of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in High-risk Adults | No dispute reported | 06/30/2026 | 1252992474 |
| Principal investigator 1 | ModernaTX, Inc. | $6,345.44 | 10/22/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age | No dispute reported | 06/30/2026 | 1252992874 |
| Principal investigator 1 | ModernaTX, Inc. | $3,572.55 | 10/17/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Study of mRNA-based Influenza and SARS-CoV-2 (COVID-19) Multi-component Vaccines in Healthy Adults | No dispute reported | 06/30/2026 | 1252992522 |
| Principal investigator 1 | ModernaTX, Inc. | $50.00 | 10/15/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants | No dispute reported | 06/30/2026 | 1252992526 |
| Principal investigator 1 | ModernaTX, Inc. | $76.86 | 10/15/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants | No dispute reported | 06/30/2026 | 1252992528 |
| Principal investigator 1 | ModernaTX, Inc. | $129.86 | 10/15/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants | No dispute reported | 06/30/2026 | 1252992546 |
| Principal investigator 1 | ModernaTX, Inc. | $132.50 | 10/15/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants | No dispute reported | 06/30/2026 | 1252992548 |
| Principal investigator 1 | ModernaTX, Inc. | $753.00 | 10/15/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants | No dispute reported | 06/30/2026 | 1252992722 |
| Principal investigator 1 | ModernaTX, Inc. | $92.00 | 10/15/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants | No dispute reported | 06/30/2026 | 1252992806 |
| Principal investigator 1 | PFIZER INC. | $28,487.60 | 10/11/2025 | Non-covered Recipient Entity Dynamed Clinical Research LP | A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1228825153 |
| Principal investigator 1 | ABBVIE INC. | $1,349.13 | 10/09/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate | No dispute reported | 06/30/2026 | 1202514201 |
| Principal investigator 1 | Bavarian Nordic A/S | $470.38 | 10/08/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | EBSI-CV-317-008 | No dispute reported | 06/30/2026 | 1250214152 |
| Principal investigator 1 | ModernaTX, Inc. | $132.50 | 10/08/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants | No dispute reported | 06/30/2026 | 1252992574 |
| Principal investigator 1 | ModernaTX, Inc. | $276.00 | 10/08/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants | No dispute reported | 06/30/2026 | 1252992706 |
| Principal investigator 1 | ModernaTX, Inc. | $2,259.00 | 10/08/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants | No dispute reported | 06/30/2026 | 1252992724 |
| Principal investigator 1 | ModernaTX, Inc. | $75.00 | 10/08/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants | No dispute reported | 06/30/2026 | 1252992824 |
| Principal investigator 1 | PFIZER INC. | $574.00 | 10/06/2025 | Non-covered Recipient Entity DM Clinical Research Cyfair | A PHASE 12 RANDOMIZED DOUBLEBLIND TRIAL OF THE SAFETY AND IMMUNOGENICITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE IN ADULTS 18 YEARS OF AGE AND OLDER | No dispute reported | 06/30/2026 | 1228719322 |
| Principal investigator 1 | ModernaTX, Inc. | $331.25 | 10/03/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants | No dispute reported | 06/30/2026 | 1252992400 |
| Principal investigator 1 | ModernaTX, Inc. | $25.00 | 10/03/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants | No dispute reported | 06/30/2026 | 1252992682 |
| Principal investigator 1 | ModernaTX, Inc. | $2,259.00 | 10/03/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants | No dispute reported | 06/30/2026 | 1252992686 |
| Principal investigator 1 | ModernaTX, Inc. | $276.00 | 10/03/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants | No dispute reported | 06/30/2026 | 1252992688 |
| Principal investigator 1 | ModernaTX, Inc. | $286.20 | 10/03/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants | No dispute reported | 06/30/2026 | 1252992704 |
| Principal investigator 1 | ModernaTX, Inc. | $357.00 | 10/03/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 | No dispute reported | 06/30/2026 | 1252992730 |
| Principal investigator 1 | Bavarian Nordic A/S | $503.51 | 10/01/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | EBSI-CV-317-008 | No dispute reported | 06/30/2026 | 1250214160 |
| Principal investigator 1 | Bavarian Nordic A/S | $364.88 | 10/01/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | EBSI-CV-317-008 | No dispute reported | 06/30/2026 | 1250214164 |
| Principal investigator 1 | PFIZER INC. | $861.00 | 10/01/2025 | Non-covered Recipient Entity DM Clinical Research Cyfair | A PHASE 12 RANDOMIZED DOUBLEBLIND TRIAL OF THE SAFETY AND IMMUNOGENICITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE IN ADULTS 18 YEARS OF AGE AND OLDER | No dispute reported | 06/30/2026 | 1228719324 |
| Principal investigator 1 | PFIZER INC. | $2,168.00 | 09/30/2025 | Non-covered Recipient Entity Dynamed Clinical Research LP | A PHASE 12 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1228827747 |
| Principal investigator 1 | ModernaTX, Inc. | $1,451.58 | 09/29/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants | No dispute reported | 06/30/2026 | 1252992530 |
| Principal investigator 1 | ModernaTX, Inc. | $13.85 | 09/29/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants | No dispute reported | 06/30/2026 | 1252992552 |
| Principal investigator 1 | PFIZER INC. | $757.50 | 09/29/2025 | Non-covered Recipient Entity DM Clinical Research Cyfair | A PHASE 3 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BNT162B2 RNABASED VARIANTADAPTED VACCINE CANDIDATES AGAINST SARSCOV2 IN PARTICIPANTS 12 THROUGH 64 YEARS OF AGE CONSIDERED AT HIGHER RISK OF SEVERE COVID19 AND PARTICIPANTS 65 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228807554 |
| Principal investigator 1 | PFIZER INC. | $615.50 | 09/29/2025 | Non-covered Recipient Entity DM Clinical Research Cyfair | A PHASE 3 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BNT162B2 RNABASED VARIANTADAPTED VACCINE CANDIDATES AGAINST SARSCOV2 IN PARTICIPANTS 12 THROUGH 64 YEARS OF AGE CONSIDERED AT HIGHER RISK OF SEVERE COVID19 AND PARTICIPANTS 65 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228807560 |
| Principal investigator 1 | PFIZER INC. | $35.00 | 09/27/2025 | Non-covered Recipient Entity Dynamed Clinical Research LP dba DM Clinical Research | A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE | No dispute reported | 06/30/2026 | 1228704800 |
| Principal investigator 1 | PFIZER INC. | $1,350.00 | 09/27/2025 | Non-covered Recipient Entity Dynamed Clinical Research LP dba DM Clinical Research | A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE | No dispute reported | 06/30/2026 | 1228704806 |
| Principal investigator 1 | PFIZER INC. | $35.00 | 09/27/2025 | Non-covered Recipient Entity Dynamed Clinical Research LP dba DM Clinical Research | A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE | No dispute reported | 06/30/2026 | 1228704964 |
| Principal investigator 1 | PFIZER INC. | $600.00 | 09/27/2025 | Non-covered Recipient Entity Dynamed Clinical Research LP dba DM Clinical Research | A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE | No dispute reported | 06/30/2026 | 1228705008 |
| Principal investigator 1 | PFIZER INC. | $35.00 | 09/27/2025 | Non-covered Recipient Entity Dynamed Clinical Research LP dba DM Clinical Research | A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE | No dispute reported | 06/30/2026 | 1228705098 |
| Principal investigator 1 | PFIZER INC. | $35.00 | 09/27/2025 | Non-covered Recipient Entity Dynamed Clinical Research LP dba DM Clinical Research | A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE | No dispute reported | 06/30/2026 | 1228705100 |
| Principal investigator 1 | PFIZER INC. | $38,458.26 | 09/27/2025 | Non-covered Recipient Entity Dynamed Clinical Research LP | A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1228825872 |
| Principal investigator 1 | ModernaTX, Inc. | $2,870.79 | 09/26/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Study to Investigate the Immunogenicity and Safety of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in High-risk Adults | No dispute reported | 06/30/2026 | 1252992462 |
| Principal investigator 1 | ABBVIE INC. | $72.00 | 09/25/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate | No dispute reported | 06/30/2026 | 1202512326 |
| Principal investigator 1 | PFIZER INC. | $738.60 | 09/25/2025 | Non-covered Recipient Entity DM Clinical Research CyFair | A PHASE 12 RANDOMIZED DOUBLEBLIND TRIAL OF THE SAFETY AND IMMUNOGENICITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE IN ADULTS 18 YEARS OF AGE AND OLDER | No dispute reported | 06/30/2026 | 1228814529 |
| Principal investigator 1 | PFIZER INC. | $819.02 | 09/25/2025 | Non-covered Recipient Entity DM Clinical Research CyFair | A PHASE 12 RANDOMIZED DOUBLEBLIND TRIAL OF THE SAFETY AND IMMUNOGENICITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE IN ADULTS 18 YEARS OF AGE AND OLDER | No dispute reported | 06/30/2026 | 1228814534 |
| Principal investigator 1 | ModernaTX, Inc. | $33.75 | 09/24/2025 | Non-covered Recipient Entity CYFAIR | A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants | No dispute reported | 06/30/2026 | 1252992426 |
| Principal investigator 1 | ModernaTX, Inc. | $12,489.06 | 09/24/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Study to Investigate the Immunogenicity and Safety of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in High-risk Adults | No dispute reported | 06/30/2026 | 1252992464 |
| Principal investigator 1 | ModernaTX, Inc. | $2,651.36 | 09/24/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Study of mRNA-1647 Cytomegalovirus Vaccine in Healthy Participants 9 to 15 Years of Age and Participants 16 to 25 Years of Age | No dispute reported | 06/30/2026 | 1252992634 |
| Principal investigator 1 | ModernaTX, Inc. | $1,221.67 | 09/24/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Study of mRNA-1647 Cytomegalovirus Vaccine in Healthy Participants 9 to 15 Years of Age and Participants 16 to 25 Years of Age | No dispute reported | 06/30/2026 | 1252992860 |
| Principal investigator 1 | ModernaTX, Inc. | $1,987.50 | 09/24/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age | No dispute reported | 06/30/2026 | 1252992880 |
| Principal investigator 1 | PFIZER INC. | $1,722.00 | 09/24/2025 | Non-covered Recipient Entity DM Clinical Research Cyfair | A PHASE 12 RANDOMIZED DOUBLEBLIND TRIAL OF THE SAFETY AND IMMUNOGENICITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE IN ADULTS 18 YEARS OF AGE AND OLDER | No dispute reported | 06/30/2026 | 1228719320 |
| Principal investigator 1 | PFIZER INC. | $25,714.08 | 09/24/2025 | Non-covered Recipient Entity Dynamed Clinical Research LP | A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1228825836 |
| Principal investigator 1 | PFIZER INC. | $7,300.56 | 09/24/2025 | Non-covered Recipient Entity Dynamed Clinical Research LP | A PHASE 12 RANDOMIZED DOUBLEBLIND TRIAL OF THE SAFETY AND IMMUNOGENICITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE IN ADULTS 18 YEARS OF AGE AND OLDER | No dispute reported | 06/30/2026 | 1228826864 |
| Principal investigator 1 | ModernaTX, Inc. | $374.98 | 09/19/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Study of mRNA-1647 Cytomegalovirus Vaccine in Healthy Participants 9 to 15 Years of Age and Participants 16 to 25 Years of Age | No dispute reported | 06/30/2026 | 1252992504 |
| Principal investigator 1 | ModernaTX, Inc. | $1,841.77 | 09/19/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Study of mRNA-1647 Cytomegalovirus Vaccine in Healthy Participants 9 to 15 Years of Age and Participants 16 to 25 Years of Age | No dispute reported | 06/30/2026 | 1252992632 |
| Principal investigator 1 | ModernaTX, Inc. | $18,009.43 | 09/19/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age | No dispute reported | 06/30/2026 | 1252992656 |
| Principal investigator 1 | Bavarian Nordic A/S | $251.75 | 09/12/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | EBSI-CV-317-008 | No dispute reported | 06/30/2026 | 1250214174 |
| Principal investigator 1 | Lexicon Pharmaceuticals, Inc. | $1,456.55 | 09/10/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | LX9211.1-204-DPN | No dispute reported | 06/30/2026 | 1248067625 |
| Principal investigator 1 | PFIZER INC. | $31,336.36 | 09/09/2025 | Non-covered Recipient Entity Dynamed Clinical Research LP | A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1228826160 |
| Principal investigator 1 | Bavarian Nordic A/S | $430.63 | 09/03/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | EBSI-CV-317-008 | No dispute reported | 06/30/2026 | 1250214166 |
| Principal investigator 1 | ModernaTX, Inc. | $422.63 | 09/03/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Clinical Study to Investigate the Safety and Immunogenicity in Relation to Product Attributes of mRNA-1083 (Severe Acute Respiratory Syndrome Coronavirus 2 [SARS-CoV-2] and Influenza Vaccine) | No dispute reported | 06/30/2026 | 1252992398 |
| Principal investigator 1 | ModernaTX, Inc. | $500.00 | 09/03/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 | No dispute reported | 06/30/2026 | 1252992442 |
| Principal investigator 1 | ModernaTX, Inc. | $1,500.00 | 09/03/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 | No dispute reported | 06/30/2026 | 1252992446 |
| Principal investigator 1 | ModernaTX, Inc. | $800.00 | 09/03/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 | No dispute reported | 06/30/2026 | 1252992448 |
| Principal investigator 1 | ModernaTX, Inc. | $995.94 | 09/03/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 | No dispute reported | 06/30/2026 | 1252992450 |
| Principal investigator 1 | ModernaTX, Inc. | $3,450.00 | 09/03/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 | No dispute reported | 06/30/2026 | 1252992456 |
| Principal investigator 1 | ModernaTX, Inc. | $1,600.00 | 09/03/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 | No dispute reported | 06/30/2026 | 1252992596 |
| Principal investigator 1 | ModernaTX, Inc. | $1,000.00 | 09/03/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 | No dispute reported | 06/30/2026 | 1252992732 |
| Principal investigator 1 | ModernaTX, Inc. | $750.00 | 09/03/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 | No dispute reported | 06/30/2026 | 1252992740 |
| Principal investigator 1 | PFIZER INC. | $10,832.25 | 09/03/2025 | Non-covered Recipient Entity Dynamed Clinical Research LP | A PHASE 12 RANDOMIZED DOUBLEBLIND TRIAL OF THE SAFETY AND IMMUNOGENICITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE IN ADULTS 18 YEARS OF AGE AND OLDER | No dispute reported | 06/30/2026 | 1228827739 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $300.00 | 09/03/2025 | Non-covered Recipient Entity Dynamed Clinical Research LP | A Phase 2a/b, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of Subcutaneous Amlitelimab in Adult Patients With Nonresponsive Celiac Disease as an Adjunct to a Gluten-free Diet | No dispute reported | 06/30/2026 | 1226135737 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $5,216.00 | 09/03/2025 | Non-covered Recipient Entity Dynamed Clinical Research LP | A Phase 2a/b, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of Subcutaneous Amlitelimab in Adult Patients With Nonresponsive Celiac Disease as an Adjunct to a Gluten-free Diet | No dispute reported | 06/30/2026 | 1226135741 |
| Principal investigator 1 | Bavarian Nordic A/S | $4,638.26 | 09/02/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | EBSI-CV-317-008 | No dispute reported | 06/30/2026 | 1250214108 |
| Principal investigator 1 | Bavarian Nordic A/S | $2,633.38 | 09/02/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | EBSI-CV-317-008 | No dispute reported | 06/30/2026 | 1250214126 |
| Principal investigator 1 | ModernaTX, Inc. | $4,759.35 | 09/02/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Study of mRNA-1647 Cytomegalovirus Vaccine in Healthy Participants 9 to 15 Years of Age and Participants 16 to 25 Years of Age | No dispute reported | 06/30/2026 | 1252992502 |
| Principal investigator 1 | ModernaTX, Inc. | $193.83 | 08/28/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants | No dispute reported | 06/30/2026 | 1252992556 |
| Principal investigator 1 | ModernaTX, Inc. | $180.00 | 08/28/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants | No dispute reported | 06/30/2026 | 1252992702 |
| Principal investigator 1 | ModernaTX, Inc. | $483.86 | 08/28/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants | No dispute reported | 06/30/2026 | 1252992710 |
| Principal investigator 1 | ModernaTX, Inc. | $2,351.85 | 08/28/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants | No dispute reported | 06/30/2026 | 1252992808 |
| Principal investigator 1 | ModernaTX, Inc. | $6,889.88 | 08/28/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants | No dispute reported | 06/30/2026 | 1252992828 |
| Principal investigator 1 | ModernaTX, Inc. | $83.10 | 08/28/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants | No dispute reported | 06/30/2026 | 1252992832 |
| Principal investigator 1 | ModernaTX, Inc. | $3,545.64 | 08/28/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants | No dispute reported | 06/30/2026 | 1252992836 |
| Principal investigator 1 | ModernaTX, Inc. | $7,113.60 | 08/28/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253009756 |
| Principal investigator 1 | ModernaTX, Inc. | $397.50 | 08/27/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age | No dispute reported | 06/30/2026 | 1252992876 |
| Principal investigator 1 | PFIZER INC. | $16,123.97 | 08/27/2025 | Non-covered Recipient Entity Dynamed Clinical Research LP | A PHASE 12 RANDOMIZED DOUBLEBLIND TRIAL OF THE SAFETY AND IMMUNOGENICITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE IN ADULTS 18 YEARS OF AGE AND OLDER | No dispute reported | 06/30/2026 | 1228830457 |
| Principal investigator 1 | Amgen Inc. | $1,248.00 | 08/25/2025 | Non-covered Recipient Entity DM CLINICAL RESEARCH | A Study to Evaluate the Efficacy, Safety & Tolerability of Maridebart Cafraglutide in Adults With T2DM | No dispute reported | 06/30/2026 | 1246640851 |
| Principal investigator 1 | ModernaTX, Inc. | $1,506.00 | 08/22/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants | No dispute reported | 06/30/2026 | 1252992430 |
| Principal investigator 1 | ModernaTX, Inc. | $550.00 | 08/22/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants | No dispute reported | 06/30/2026 | 1252992436 |
| Principal investigator 1 | ModernaTX, Inc. | $184.00 | 08/22/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants | No dispute reported | 06/30/2026 | 1252992540 |
| Principal investigator 1 | ModernaTX, Inc. | $2,500.00 | 08/22/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants | No dispute reported | 06/30/2026 | 1252992560 |
| Principal investigator 1 | ModernaTX, Inc. | $1,750.00 | 08/22/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants | No dispute reported | 06/30/2026 | 1252992566 |
| Principal investigator 1 | ModernaTX, Inc. | $92,822.21 | 08/22/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Study to Investigate the Immunogenicity and Safety of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in High-risk Adults | No dispute reported | 06/30/2026 | 1252992624 |
| Principal investigator 1 | ModernaTX, Inc. | $265.00 | 08/22/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants | No dispute reported | 06/30/2026 | 1252992700 |
| Principal investigator 1 | ModernaTX, Inc. | $50.00 | 08/22/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants | No dispute reported | 06/30/2026 | 1252992720 |
| Principal investigator 1 | ModernaTX, Inc. | $8,165.92 | 08/20/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Study to Investigate the Immunogenicity and Safety of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in High-risk Adults | No dispute reported | 06/30/2026 | 1252992476 |
| Principal investigator 1 | ModernaTX, Inc. | $7,826.80 | 08/20/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age | No dispute reported | 06/30/2026 | 1252992870 |
| Principal investigator 1 | ModernaTX, Inc. | $484.96 | 08/13/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Study to Investigate the Immunogenicity and Safety of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in High-risk Adults | No dispute reported | 06/30/2026 | 1252992608 |
| Principal investigator 1 | ModernaTX, Inc. | $68.90 | 08/13/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Study of mRNA-1647 Cytomegalovirus Vaccine in Healthy Participants 9 to 15 Years of Age and Participants 16 to 25 Years of Age | No dispute reported | 06/30/2026 | 1252992640 |
| Principal investigator 1 | ModernaTX, Inc. | $500.86 | 08/13/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Study of mRNA-1647 Cytomegalovirus Vaccine in Healthy Participants 9 to 15 Years of Age and Participants 16 to 25 Years of Age | No dispute reported | 06/30/2026 | 1252992642 |
| Principal investigator 1 | ModernaTX, Inc. | $28,209.89 | 08/13/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Study of mRNA-1647 Cytomegalovirus Vaccine in Healthy Participants 9 to 15 Years of Age and Participants 16 to 25 Years of Age | No dispute reported | 06/30/2026 | 1252992862 |
| Principal investigator 1 | ModernaTX, Inc. | $2,318.76 | 08/13/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Study of mRNA-1647 Cytomegalovirus Vaccine in Healthy Participants 9 to 15 Years of Age and Participants 16 to 25 Years of Age | No dispute reported | 06/30/2026 | 1252992866 |
| Principal investigator 1 | Bavarian Nordic A/S | $371.63 | 08/06/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | EBSI-CV-317-008 | No dispute reported | 06/30/2026 | 1250214176 |
| Principal investigator 1 | PFIZER INC. | $8,546.28 | 08/05/2025 | Non-covered Recipient Entity Dynamed Clinical Research LP | A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1228828533 |
| Principal investigator 1 | ModernaTX, Inc. | $526.11 | 08/04/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants | No dispute reported | 06/30/2026 | 1252992408 |
| Principal investigator 1 | ModernaTX, Inc. | $7,055.55 | 08/04/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants | No dispute reported | 06/30/2026 | 1252992536 |
| Principal investigator 1 | ModernaTX, Inc. | $1,722.47 | 08/04/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants | No dispute reported | 06/30/2026 | 1252992542 |
| Principal investigator 1 | ModernaTX, Inc. | $1,772.82 | 08/04/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants | No dispute reported | 06/30/2026 | 1252992708 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $10,432.00 | 08/04/2025 | Non-covered Recipient Entity Dynamed Clinical Research LP | A Phase 2a/b, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of Subcutaneous Amlitelimab in Adult Patients With Nonresponsive Celiac Disease as an Adjunct to a Gluten-free Diet | No dispute reported | 06/30/2026 | 1226135705 |
| Principal investigator 1 | PFIZER INC. | $1,028.20 | 08/02/2025 | Non-covered Recipient Entity Dynamed Clinical Research LP | A PHASE 12 RANDOMIZED DOUBLEBLIND TRIAL OF THE SAFETY AND IMMUNOGENICITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE IN ADULTS 18 YEARS OF AGE AND OLDER | No dispute reported | 06/30/2026 | 1228830494 |
| Principal investigator 1 | Bavarian Nordic A/S | $8,628.57 | 08/01/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | EBSI-CV-317-008 | No dispute reported | 06/30/2026 | 1250214110 |
| Principal investigator 1 | Bavarian Nordic A/S | $280.42 | 08/01/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | EBSI-CV-317-008 | No dispute reported | 06/30/2026 | 1250214168 |
| Principal investigator 1 | ModernaTX, Inc. | $10,087.32 | 08/01/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Study to Investigate the Immunogenicity and Safety of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in High-risk Adults | No dispute reported | 06/30/2026 | 1252992850 |
| Principal investigator 1 | PFIZER INC. | $96,164.96 | 08/01/2025 | Non-covered Recipient Entity Dynamed Clinical Research LP | A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1228827511 |
| Principal investigator 1 | PFIZER INC. | $21,892.20 | 07/31/2025 | Non-covered Recipient Entity Dynamed Clinical Research LP | A PHASE 12 RANDOMIZED DOUBLEBLIND TRIAL OF THE SAFETY AND IMMUNOGENICITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE IN ADULTS 18 YEARS OF AGE AND OLDER | No dispute reported | 06/30/2026 | 1228830597 |
| Principal investigator 1 | ModernaTX, Inc. | $2,351.85 | 07/30/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants | No dispute reported | 06/30/2026 | 1252992534 |
| Principal investigator 1 | ModernaTX, Inc. | $138.45 | 07/30/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants | No dispute reported | 06/30/2026 | 1252992718 |
| Principal investigator 1 | ModernaTX, Inc. | $3,545.64 | 07/30/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants | No dispute reported | 06/30/2026 | 1252992814 |
| Principal investigator 1 | ModernaTX, Inc. | $1,150.00 | 07/28/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253009746 |
| Principal investigator 1 | PFIZER INC. | $4,424.81 | 07/26/2025 | Non-covered Recipient Entity Dynamed Clinical Research LP | A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1228830191 |
| Principal investigator 1 | ModernaTX, Inc. | $255.73 | 07/23/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Study of mRNA-based Influenza and SARS-CoV-2 (COVID-19) Multi-component Vaccines in Healthy Adults | No dispute reported | 06/30/2026 | 1252992524 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $5,000.00 | 07/21/2025 | Non-covered Recipient Entity Dynamed Clinical Research LP | A Phase 2a/b, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of Subcutaneous Amlitelimab in Adult Patients With Nonresponsive Celiac Disease as an Adjunct to a Gluten-free Diet | No dispute reported | 06/30/2026 | 1226135680 |
| Principal investigator 1 | ModernaTX, Inc. | $12,934.69 | 07/18/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age | No dispute reported | 06/30/2026 | 1252992650 |
| Principal investigator 1 | PFIZER INC. | $18,530.91 | 07/11/2025 | Non-covered Recipient Entity Dynamed Clinical Research LP | A PHASE 12 RANDOMIZED DOUBLEBLIND TRIAL OF THE SAFETY AND IMMUNOGENICITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE IN ADULTS 18 YEARS OF AGE AND OLDER | No dispute reported | 06/30/2026 | 1228830658 |
| Principal investigator 1 | ModernaTX, Inc. | $772.48 | 07/09/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Study to Investigate the Immunogenicity and Safety of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in High-risk Adults | No dispute reported | 06/30/2026 | 1252992610 |
| Principal investigator 1 | ModernaTX, Inc. | $1,926.00 | 07/09/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Study to Investigate the Immunogenicity and Safety of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in High-risk Adults | No dispute reported | 06/30/2026 | 1252992614 |
| Principal investigator 1 | ModernaTX, Inc. | $1,000.00 | 07/09/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Study to Investigate the Immunogenicity and Safety of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in High-risk Adults | No dispute reported | 06/30/2026 | 1252992760 |
| Principal investigator 1 | PFIZER INC. | $4,306.30 | 07/09/2025 | Non-covered Recipient Entity Dynamed Clinical Research LP | A PHASE 12 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1228830048 |
| Principal investigator 1 | PFIZER INC. | $201,745.90 | 07/08/2025 | Non-covered Recipient Entity Dynamed Clinical Research LP | A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1228830106 |
| Principal investigator 1 | Bavarian Nordic A/S | $231.88 | 07/07/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | EBSI-CV-317-008 | No dispute reported | 06/30/2026 | 1250214170 |
| Principal investigator 1 | Bavarian Nordic A/S | $74.00 | 07/07/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | EBSI-CV-317-008 | No dispute reported | 06/30/2026 | 1250214172 |
| Principal investigator 1 | ModernaTX, Inc. | $728.75 | 07/07/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | Study of mRNA-1010 Seasonal Influenza Vaccine in Adults | No dispute reported | 06/30/2026 | 1252992668 |
| Principal investigator 1 | ABBVIE INC. | $1,349.13 | 07/02/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate | No dispute reported | 06/30/2026 | 1202495609 |
| Principal investigator 1 | ModernaTX, Inc. | $795.00 | 07/02/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age | No dispute reported | 06/30/2026 | 1252992512 |
| Principal investigator 1 | ModernaTX, Inc. | $642.00 | 07/02/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Study to Investigate the Immunogenicity and Safety of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in High-risk Adults | No dispute reported | 06/30/2026 | 1252992750 |
| Principal investigator 1 | ModernaTX, Inc. | $106.00 | 07/02/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Study to Investigate the Immunogenicity and Safety of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in High-risk Adults | No dispute reported | 06/30/2026 | 1252992768 |
| Principal investigator 1 | ModernaTX, Inc. | $13,854.57 | 07/02/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Study to Investigate the Immunogenicity and Safety of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in High-risk Adults | No dispute reported | 06/30/2026 | 1252992846 |
| Principal investigator 1 | ModernaTX, Inc. | $636.00 | 07/02/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age | No dispute reported | 06/30/2026 | 1252992884 |
| Principal investigator 1 | PFIZER INC. | $346.16 | 07/02/2025 | Non-covered Recipient Entity Dynamed Clinical Research LP | A PHASE 12 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1228830664 |
| Principal investigator 1 | PFIZER INC. | $17,070.13 | 07/01/2025 | Non-covered Recipient Entity Dynamed Clinical Research LP | A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1228830186 |
| Principal investigator 1 | ModernaTX, Inc. | $7,113.60 | 06/27/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253009754 |
| Principal investigator 1 | PFIZER INC. | $14,311.82 | 06/26/2025 | Non-covered Recipient Entity Dynamed Clinical Research LP | A PHASE 12 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1228829527 |
| Principal investigator 1 | Bavarian Nordic A/S | $284.88 | 06/25/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | EBSI-CV-317-008 | No dispute reported | 06/30/2026 | 1250214118 |
| Principal investigator 1 | Bavarian Nordic A/S | $324.63 | 06/25/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | EBSI-CV-317-008 | No dispute reported | 06/30/2026 | 1250214120 |
| Principal investigator 1 | Bavarian Nordic A/S | $7,583.26 | 06/25/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | EBSI-CV-317-008 | No dispute reported | 06/30/2026 | 1250214236 |
| Principal investigator 1 | PFIZER INC. | $55,998.45 | 06/21/2025 | Non-covered Recipient Entity Dynamed Clinical Research LP | A PHASE 12 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1228829872 |
| Principal investigator 1 | ModernaTX, Inc. | $200.00 | 06/20/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Study to Investigate the Immunogenicity and Safety of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in High-risk Adults | No dispute reported | 06/30/2026 | 1252992460 |
| Principal investigator 1 | ModernaTX, Inc. | $1,318.40 | 06/20/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Study to Investigate the Immunogenicity and Safety of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in High-risk Adults | No dispute reported | 06/30/2026 | 1252992468 |
| Principal investigator 1 | Bavarian Nordic A/S | $231.88 | 06/18/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | EBSI-CV-317-008 | No dispute reported | 06/30/2026 | 1250214112 |
| Principal investigator 1 | Bavarian Nordic A/S | $50.00 | 06/18/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | EBSI-CV-317-008 | No dispute reported | 06/30/2026 | 1250214114 |
| Principal investigator 1 | Bavarian Nordic A/S | $74.00 | 06/18/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | EBSI-CV-317-008 | No dispute reported | 06/30/2026 | 1250214116 |
| Principal investigator 1 | ModernaTX, Inc. | $19,200.00 | 06/18/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Clinical Study to Investigate the Safety and Immunogenicity in Relation to Product Attributes of mRNA-1083 (Severe Acute Respiratory Syndrome Coronavirus 2 [SARS-CoV-2] and Influenza Vaccine) | No dispute reported | 06/30/2026 | 1252992396 |
| Principal investigator 1 | ModernaTX, Inc. | $443.04 | 06/18/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants | No dispute reported | 06/30/2026 | 1252992438 |
| Principal investigator 1 | ModernaTX, Inc. | $14,534.80 | 06/18/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants | No dispute reported | 06/30/2026 | 1252992440 |
| Principal investigator 1 | ModernaTX, Inc. | $12,224.49 | 06/18/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age | No dispute reported | 06/30/2026 | 1252992514 |
| Principal investigator 1 | ModernaTX, Inc. | $6,889.88 | 06/18/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants | No dispute reported | 06/30/2026 | 1252992558 |
| Principal investigator 1 | ModernaTX, Inc. | $2,365.20 | 06/18/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants | No dispute reported | 06/30/2026 | 1252992582 |
| Principal investigator 1 | ModernaTX, Inc. | $5,318.46 | 06/18/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants | No dispute reported | 06/30/2026 | 1252992692 |
| Principal investigator 1 | ModernaTX, Inc. | $5,309.62 | 06/18/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Clinical Study to Investigate the Safety and Immunogenicity in Relation to Product Attributes of mRNA-1083 (Severe Acute Respiratory Syndrome Coronavirus 2 [SARS-CoV-2] and Influenza Vaccine) | No dispute reported | 06/30/2026 | 1252992804 |
| Principal investigator 1 | ModernaTX, Inc. | $354.00 | 06/18/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253009744 |
| Principal investigator 1 | ModernaTX, Inc. | $334,339.20 | 06/18/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253009758 |
| Principal investigator 1 | ABBVIE INC. | $72.00 | 06/17/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate | No dispute reported | 06/30/2026 | 1202491837 |
| Principal investigator 1 | PFIZER INC. | $135.32 | 06/17/2025 | Non-covered Recipient Entity Dynamed Clinical Research LP dba DM Clinical Research | A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE | No dispute reported | 06/30/2026 | 1228704804 |
| Principal investigator 1 | PFIZER INC. | $124.05 | 06/17/2025 | Non-covered Recipient Entity Dynamed Clinical Research LP dba DM Clinical Research | A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE | No dispute reported | 06/30/2026 | 1228704966 |
| Principal investigator 1 | PFIZER INC. | $37.70 | 06/17/2025 | Non-covered Recipient Entity Dynamed Clinical Research LP dba DM Clinical Research | A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE | No dispute reported | 06/30/2026 | 1228705148 |
| Principal investigator 1 | PFIZER INC. | $135.32 | 06/17/2025 | Non-covered Recipient Entity Dynamed Clinical Research LP dba DM Clinical Research | A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE | No dispute reported | 06/30/2026 | 1228705162 |
| Principal investigator 1 | PFIZER INC. | $35.00 | 06/17/2025 | Non-covered Recipient Entity Dynamed Clinical Research LP dba DM Clinical Research | A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE | No dispute reported | 06/30/2026 | 1228705332 |
| Principal investigator 1 | Seqirus USA Inc | $550.00 | 06/16/2025 | Non-covered Recipient Entity Dynamed Clinical Research | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1185296448 |
| Principal investigator 1 | Seqirus USA Inc | $1,320.00 | 06/16/2025 | Non-covered Recipient Entity Dynamed Clinical Research | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1185296450 |
| Principal investigator 1 | Seqirus USA Inc | $1,000.00 | 06/16/2025 | Non-covered Recipient Entity Dynamed Clinical Research | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1185296452 |
| Principal investigator 1 | Seqirus USA Inc | $2,000.00 | 06/16/2025 | Non-covered Recipient Entity Dynamed Clinical Research | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1185296454 |
| Principal investigator 1 | Seqirus USA Inc | $1,500.00 | 06/16/2025 | Non-covered Recipient Entity Dynamed Clinical Research | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1185296460 |
| Principal investigator 1 | Seqirus USA Inc | $1,000.00 | 06/16/2025 | Non-covered Recipient Entity Dynamed Clinical Research | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1185296462 |
| Principal investigator 1 | PFIZER INC. | $1,384.64 | 06/14/2025 | Non-covered Recipient Entity Dynamed Clinical Research LP | A PHASE 12 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1228829810 |
| Principal investigator 1 | Bavarian Nordic A/S | $798.58 | 06/13/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | EBSI-CV-317-008 | No dispute reported | 06/30/2026 | 1250214238 |
| Principal investigator 1 | PFIZER INC. | $136,889.62 | 06/10/2025 | Non-covered Recipient Entity Dynamed Clinical Research LP | A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1228829372 |
| Principal investigator 1 | Bavarian Nordic A/S | $1,282.92 | 06/06/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | EBSI-CV-317-008 | No dispute reported | 06/30/2026 | 1250214078 |
| Principal investigator 1 | ModernaTX, Inc. | $1,429.75 | 06/04/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Study to Investigate the Immunogenicity and Safety of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in High-risk Adults | No dispute reported | 06/30/2026 | 1252992482 |
| Principal investigator 1 | ModernaTX, Inc. | $1,878.88 | 06/04/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Study to Investigate the Immunogenicity and Safety of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in High-risk Adults | No dispute reported | 06/30/2026 | 1252992762 |
| Principal investigator 1 | Bavarian Nordic A/S | $5,539.43 | 06/02/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | EBSI-CV-317-008 | No dispute reported | 06/30/2026 | 1250214240 |
| Principal investigator 1 | PFIZER INC. | $14,044.31 | 05/30/2025 | Non-covered Recipient Entity Dynamed Clinical Research LP | A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1228832899 |
| Principal investigator 1 | ModernaTX, Inc. | $526.11 | 05/28/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants | No dispute reported | 06/30/2026 | 1252992434 |
| Principal investigator 1 | ModernaTX, Inc. | $5,764.18 | 05/28/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Study to Investigate the Immunogenicity and Safety of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in High-risk Adults | No dispute reported | 06/30/2026 | 1252992484 |
| Principal investigator 1 | ModernaTX, Inc. | $3,545.64 | 05/28/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants | No dispute reported | 06/30/2026 | 1252992696 |
| Principal investigator 1 | ModernaTX, Inc. | $3,655.58 | 05/28/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Study of mRNA-based Influenza and SARS-CoV-2 (COVID-19) Multi-component Vaccines in Healthy Adults | No dispute reported | 06/30/2026 | 1252992800 |
| Principal investigator 1 | ModernaTX, Inc. | $9,460.80 | 05/28/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants | No dispute reported | 06/30/2026 | 1252992812 |
| Principal investigator 1 | ModernaTX, Inc. | $279,801.60 | 05/28/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253009748 |
| Principal investigator 1 | ModernaTX, Inc. | $2,478.00 | 05/28/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253009752 |
| Principal investigator 1 | PFIZER INC. | $184.50 | 05/28/2025 | Non-covered Recipient Entity DM Clin Research Houston | A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1228814632 |
| Principal investigator 1 | PFIZER INC. | $211.65 | 05/28/2025 | Non-covered Recipient Entity DM Clin Research Houston | A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1228814681 |
| Principal investigator 1 | PFIZER INC. | $1,089.15 | 05/27/2025 | Non-covered Recipient Entity DM Clinical ResearchCyfair | A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1228707668 |
| Principal investigator 1 | PFIZER INC. | $1,089.15 | 05/27/2025 | Non-covered Recipient Entity DM Clinical Research | A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1228828047 |
| Principal investigator 1 | Bavarian Nordic A/S | $231.88 | 05/23/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | EBSI-CV-317-008 | No dispute reported | 06/30/2026 | 1250214122 |
| Principal investigator 1 | Bavarian Nordic A/S | $74.00 | 05/23/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | EBSI-CV-317-008 | No dispute reported | 06/30/2026 | 1250214124 |
| Principal investigator 1 | Bavarian Nordic A/S | $231.88 | 05/23/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | EBSI-CV-317-008 | No dispute reported | 06/30/2026 | 1250214254 |
| Principal investigator 1 | Bavarian Nordic A/S | $74.00 | 05/23/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | EBSI-CV-317-008 | No dispute reported | 06/30/2026 | 1250214256 |
| Principal investigator 1 | ModernaTX, Inc. | $9,867.31 | 05/21/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age | No dispute reported | 06/30/2026 | 1252992882 |
| Principal investigator 1 | PFIZER INC. | $72.61 | 05/21/2025 | Non-covered Recipient Entity DM Clinical ResearchCyfair | A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1228707838 |
| Principal investigator 1 | PFIZER INC. | $18.98 | 05/21/2025 | Non-covered Recipient Entity DM Clinical ResearchCyfair | A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1228707842 |
| Principal investigator 1 | PFIZER INC. | $18.98 | 05/21/2025 | Non-covered Recipient Entity DM Clinical Research | A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1228828038 |
| Principal investigator 1 | PFIZER INC. | $72.61 | 05/21/2025 | Non-covered Recipient Entity DM Clinical Research | A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1228828056 |
| Principal investigator 1 | Bavarian Nordic A/S | $5,861.88 | 05/16/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | EBSI-CV-317-008 | No dispute reported | 06/30/2026 | 1250214106 |
| Principal investigator 1 | PFIZER INC. | $88,343.40 | 05/15/2025 | Non-covered Recipient Entity Dynamed Clinical Research LP | A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1228832749 |
| Principal investigator 1 | ABBVIE INC. | $147.00 | 05/13/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate | No dispute reported | 06/30/2026 | 1202484721 |
| Principal investigator 1 | ModernaTX, Inc. | $499.19 | 05/09/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Study of mRNA-based Influenza and SARS-CoV-2 (COVID-19) Multi-component Vaccines in Healthy Adults | No dispute reported | 06/30/2026 | 1252992390 |
| Principal investigator 1 | PFIZER INC. | $50,053.36 | 05/08/2025 | Non-covered Recipient Entity Dynamed Clinical Research LP | A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1228832912 |
| Principal investigator 1 | Bavarian Nordic A/S | $231.88 | 05/07/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | EBSI-CV-317-008 | No dispute reported | 06/30/2026 | 1250214128 |
| Principal investigator 1 | Bavarian Nordic A/S | $74.00 | 05/07/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | EBSI-CV-317-008 | No dispute reported | 06/30/2026 | 1250214130 |
| Principal investigator 1 | Bavarian Nordic A/S | $430.63 | 05/07/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | EBSI-CV-317-008 | No dispute reported | 06/30/2026 | 1250214132 |
| Principal investigator 1 | Bavarian Nordic A/S | $470.38 | 05/07/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | EBSI-CV-317-008 | No dispute reported | 06/30/2026 | 1250214222 |
| Principal investigator 1 | Bavarian Nordic A/S | $231.88 | 05/07/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | EBSI-CV-317-008 | No dispute reported | 06/30/2026 | 1250214258 |
| Principal investigator 1 | Bavarian Nordic A/S | $74.00 | 05/07/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | EBSI-CV-317-008 | No dispute reported | 06/30/2026 | 1250214260 |
| Principal investigator 1 | ABBVIE INC. | $1,349.13 | 05/06/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate | No dispute reported | 06/30/2026 | 1202481565 |
| Principal investigator 1 | PFIZER INC. | $615.00 | 05/06/2025 | Non-covered Recipient Entity DM Clin Research Houston | A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1228814673 |
| Principal investigator 1 | PFIZER INC. | $705.50 | 05/06/2025 | Non-covered Recipient Entity DM Clin Research Houston | A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1228814687 |
| Principal investigator 1 | ModernaTX, Inc. | $1,272.00 | 04/30/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants | No dispute reported | 06/30/2026 | 1252992402 |
| Principal investigator 1 | ModernaTX, Inc. | $1,166.00 | 04/30/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants | No dispute reported | 06/30/2026 | 1252992410 |
| Principal investigator 1 | ModernaTX, Inc. | $106.00 | 04/30/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants | No dispute reported | 06/30/2026 | 1252992424 |
| Principal investigator 1 | ModernaTX, Inc. | $1,060.00 | 04/30/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants | No dispute reported | 06/30/2026 | 1252992432 |
| Principal investigator 1 | ModernaTX, Inc. | $954.00 | 04/30/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants | No dispute reported | 06/30/2026 | 1252992578 |
| Principal investigator 1 | ModernaTX, Inc. | $1,696.00 | 04/30/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants | No dispute reported | 06/30/2026 | 1252992580 |
| Principal investigator 1 | ModernaTX, Inc. | $2,120.00 | 04/30/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants | No dispute reported | 06/30/2026 | 1252992584 |
| Principal investigator 1 | ModernaTX, Inc. | $4,956.00 | 04/28/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253009740 |
| Principal investigator 1 | Bavarian Nordic A/S | $39.75 | 04/25/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | EBSI-CV-317-008 | No dispute reported | 06/30/2026 | 1250214232 |
| Principal investigator 1 | Bavarian Nordic A/S | $547.45 | 04/25/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | EBSI-CV-317-008 | No dispute reported | 06/30/2026 | 1250214234 |
| Principal investigator 1 | PFIZER INC. | $50.00 | 04/25/2025 | Non-covered Recipient Entity Dynamed Clinical Research LP | A PHASE 12 RANDOMIZED DOUBLEBLIND TRIAL OF THE SAFETY AND IMMUNOGENICITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE IN ADULTS 18 YEARS OF AGE AND OLDER | No dispute reported | 06/30/2026 | 1228833477 |
| Principal investigator 1 | Amgen Inc. | $261,755.91 | 04/24/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Study to Evaluate the Efficacy, Safety & Tolerability of Maridebart Cafraglutide in Adults With T2DM | No dispute reported | 06/30/2026 | 1246640983 |
| Principal investigator 1 | PFIZER INC. | $245.13 | 04/24/2025 | Non-covered Recipient Entity Dynamed Clinical Research LP | A PHASE 12 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1228832863 |
| Principal investigator 1 | PFIZER INC. | $325.00 | 04/24/2025 | Non-covered Recipient Entity Dynamed Clinical Research LP | A PHASE 12 RANDOMIZED DOUBLEBLIND TRIAL OF THE SAFETY AND IMMUNOGENICITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE IN ADULTS 18 YEARS OF AGE AND OLDER | No dispute reported | 06/30/2026 | 1228833483 |
| Principal investigator 1 | Bavarian Nordic A/S | $4,626.58 | 04/18/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | EBSI-CV-317-008 | No dispute reported | 06/30/2026 | 1250214242 |
| Principal investigator 1 | ModernaTX, Inc. | $13,298.69 | 04/18/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Study to Investigate the Immunogenicity and Safety of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in High-risk Adults | No dispute reported | 06/30/2026 | 1252992758 |
| Principal investigator 1 | ModernaTX, Inc. | $4,379.13 | 04/18/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age | No dispute reported | 06/30/2026 | 1252992788 |
| Principal investigator 1 | PFIZER INC. | $46.38 | 04/18/2025 | Non-covered Recipient Entity Dynamed Clinical Research LP dba DM Clinical Research | A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE | No dispute reported | 06/30/2026 | 1228704858 |
| Principal investigator 1 | Lexicon Pharmaceuticals, Inc. | $80.00 | 04/16/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | LX9211.1-204-DPN | No dispute reported | 06/30/2026 | 1248068201 |
| Principal investigator 1 | Lexicon Pharmaceuticals, Inc. | $1,500.00 | 04/16/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | LX9211.1-204-DPN | No dispute reported | 06/30/2026 | 1248068203 |
| Principal investigator 1 | ModernaTX, Inc. | $939.44 | 04/16/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Study to Investigate the Immunogenicity and Safety of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in High-risk Adults | No dispute reported | 06/30/2026 | 1252992744 |
| Principal investigator 1 | PFIZER INC. | $4,927.26 | 04/16/2025 | Non-covered Recipient Entity Dynamed Clinical Research LP | A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1228833398 |
| Principal investigator 1 | Bavarian Nordic A/S | $231.88 | 04/11/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | EBSI-CV-317-008 | No dispute reported | 06/30/2026 | 1250214134 |
| Principal investigator 1 | Bavarian Nordic A/S | $74.00 | 04/11/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | EBSI-CV-317-008 | No dispute reported | 06/30/2026 | 1250214136 |
| Principal investigator 1 | Bavarian Nordic A/S | $298.75 | 04/11/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | EBSI-CV-317-008 | No dispute reported | 06/30/2026 | 1250214138 |
| Principal investigator 1 | Bavarian Nordic A/S | $613.70 | 04/11/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | EBSI-CV-317-008 | No dispute reported | 06/30/2026 | 1250214220 |
| Principal investigator 1 | Bavarian Nordic A/S | $231.88 | 04/11/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | EBSI-CV-317-008 | No dispute reported | 06/30/2026 | 1250214262 |
| Principal investigator 1 | Bavarian Nordic A/S | $74.00 | 04/11/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | EBSI-CV-317-008 | No dispute reported | 06/30/2026 | 1250214264 |
| Principal investigator 1 | Bavarian Nordic A/S | $231.88 | 04/11/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | EBSI-CV-317-008 | No dispute reported | 06/30/2026 | 1250214266 |
| Principal investigator 1 | Bavarian Nordic A/S | $74.00 | 04/11/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | EBSI-CV-317-008 | No dispute reported | 06/30/2026 | 1250214268 |
| Principal investigator 1 | Bavarian Nordic A/S | $231.88 | 04/11/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | EBSI-CV-317-008 | No dispute reported | 06/30/2026 | 1250214270 |
| Principal investigator 1 | Bavarian Nordic A/S | $74.00 | 04/11/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | EBSI-CV-317-008 | No dispute reported | 06/30/2026 | 1250214274 |
| Principal investigator 1 | Bavarian Nordic A/S | $231.88 | 04/11/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | EBSI-CV-317-008 | No dispute reported | 06/30/2026 | 1250214276 |
| Principal investigator 1 | ModernaTX, Inc. | $27,600.00 | 04/11/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253009762 |
| Principal investigator 1 | ModernaTX, Inc. | $124.80 | 04/11/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253009768 |
| Principal investigator 1 | ABBVIE INC. | $326.00 | 04/10/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate | No dispute reported | 06/30/2026 | 1202475584 |
| Principal investigator 1 | ABBVIE INC. | $147.00 | 04/09/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate | No dispute reported | 06/30/2026 | 1202475069 |
| Principal investigator 1 | Bavarian Nordic A/S | $231.88 | 04/09/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | EBSI-CV-317-008 | No dispute reported | 06/30/2026 | 1250214218 |
| Principal investigator 1 | Bavarian Nordic A/S | $74.00 | 04/09/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | EBSI-CV-317-008 | No dispute reported | 06/30/2026 | 1250214228 |
| Principal investigator 1 | PFIZER INC. | $7,321.98 | 04/08/2025 | Non-covered Recipient Entity Dynamed Clinical Research LP | A PHASE 12 RANDOMIZED DOUBLEBLIND TRIAL OF THE SAFETY AND IMMUNOGENICITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE IN ADULTS 18 YEARS OF AGE AND OLDER | No dispute reported | 06/30/2026 | 1228832923 |
| Principal investigator 1 | ModernaTX, Inc. | $435.00 | 04/04/2025 | Non-covered Recipient Entity CYFAIR | A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants | No dispute reported | 06/30/2026 | 1252992562 |
| Principal investigator 1 | ABBVIE INC. | $1,349.13 | 04/03/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate | No dispute reported | 06/30/2026 | 1202469176 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $26,700.00 | 04/02/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | a phase 3,global,randomized,modified double blind,placebo controlled,study to evaluate the efficacy,immunogenicity,and safety of IVX A12,a respiratory syncytial virus RSV and human metapneumovirus hMPV virus like particle VLP vaccine in adults 60 years of age and older | No dispute reported | 06/30/2026 | 1185538380 |
| Principal investigator 1 | Bavarian Nordic A/S | $430.63 | 04/02/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | EBSI-CV-317-008 | No dispute reported | 06/30/2026 | 1250214224 |
| Principal investigator 1 | Bavarian Nordic A/S | $7,417.06 | 04/02/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | EBSI-CV-317-008 | No dispute reported | 06/30/2026 | 1250214244 |
| Principal investigator 1 | Bavarian Nordic A/S | $430.63 | 04/02/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | EBSI-CV-317-008 | No dispute reported | 06/30/2026 | 1250214272 |
| Principal investigator 1 | ModernaTX, Inc. | $40,803.93 | 04/02/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | Study of mRNA-1010 Seasonal Influenza Vaccine in Adults | No dispute reported | 06/30/2026 | 1252992388 |
| Principal investigator 1 | ModernaTX, Inc. | $397.50 | 04/02/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age | No dispute reported | 06/30/2026 | 1252992660 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $16,450.00 | 04/02/2025 | Non-covered Recipient Entity Dynamed Clinical Research LP | A Phase 2a/b, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of Subcutaneous Amlitelimab in Adult Patients With Nonresponsive Celiac Disease as an Adjunct to a Gluten-free Diet | No dispute reported | 06/30/2026 | 1226135554 |
| Principal investigator 1 | Bavarian Nordic A/S | $231.88 | 04/01/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | EBSI-CV-317-008 | No dispute reported | 06/30/2026 | 1250214226 |
| Principal investigator 1 | Bavarian Nordic A/S | $4,590.22 | 04/01/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | EBSI-CV-317-008 | No dispute reported | 06/30/2026 | 1250214246 |
| Principal investigator 1 | ModernaTX, Inc. | $1,844.42 | 04/01/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Study to Investigate the Immunogenicity and Safety of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in High-risk Adults | No dispute reported | 06/30/2026 | 1252992466 |
| Principal investigator 1 | ModernaTX, Inc. | $3,210.00 | 04/01/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Study to Investigate the Immunogenicity and Safety of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in High-risk Adults | No dispute reported | 06/30/2026 | 1252992486 |
| Principal investigator 1 | ModernaTX, Inc. | $2,965.37 | 04/01/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants | No dispute reported | 06/30/2026 | 1252992822 |
| Principal investigator 1 | PFIZER INC. | $245.13 | 03/28/2025 | Non-covered Recipient Entity Dynamed Clinical Research LP | A PHASE 12 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1228832839 |
| Principal investigator 1 | PFIZER INC. | $25,176.97 | 03/28/2025 | Non-covered Recipient Entity Dynamed Clinical Research LP | A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1228833384 |
| Principal investigator 1 | Bavarian Nordic A/S | $430.63 | 03/26/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | EBSI-CV-317-008 | No dispute reported | 06/30/2026 | 1250214196 |
| Principal investigator 1 | Bavarian Nordic A/S | $583.63 | 03/26/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | EBSI-CV-317-008 | No dispute reported | 06/30/2026 | 1250214248 |
| Principal investigator 1 | ModernaTX, Inc. | $8.50 | 03/26/2025 | Non-covered Recipient Entity CYFAIR | A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants | No dispute reported | 06/30/2026 | 1252992674 |
| Principal investigator 1 | PFIZER INC. | $201.19 | 03/26/2025 | Non-covered Recipient Entity Dynamed Clinical Research LP | A PHASE 12 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1228833350 |
| Principal investigator 1 | ModernaTX, Inc. | $1,499.68 | 03/24/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 | No dispute reported | 06/30/2026 | 1252992734 |
| Principal investigator 1 | ModernaTX, Inc. | $4,248.00 | 03/24/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253009738 |
| Principal investigator 1 | PFIZER INC. | $189.80 | 03/24/2025 | Non-covered Recipient Entity DM Clinical ResearchCyfair | A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1228707758 |
| Principal investigator 1 | PFIZER INC. | $189.80 | 03/24/2025 | Non-covered Recipient Entity DM Clinical Research | A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1228827904 |
| Principal investigator 1 | PFIZER INC. | $26,496.93 | 03/22/2025 | Non-covered Recipient Entity Dynamed Clinical Research LP | A PHASE 12 RANDOMIZED DOUBLEBLIND TRIAL OF THE SAFETY AND IMMUNOGENICITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE IN ADULTS 18 YEARS OF AGE AND OLDER | No dispute reported | 06/30/2026 | 1228832773 |
| Principal investigator 1 | ModernaTX, Inc. | $13,885.10 | 03/21/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Study to Investigate the Immunogenicity and Safety of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in High-risk Adults | No dispute reported | 06/30/2026 | 1252992626 |
| Principal investigator 1 | PFIZER INC. | $500.00 | 03/20/2025 | Non-covered Recipient Entity Dynamed Clinical Research LP dba DM Clinical Research | A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE | No dispute reported | 06/30/2026 | 1228704794 |
| Principal investigator 1 | PFIZER INC. | $500.00 | 03/20/2025 | Non-covered Recipient Entity Dynamed Clinical Research LP dba DM Clinical Research | A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND TOLERABILITY OF RIMEGEPANT FOR THE PREVENTION OF MIGRAINE IN ADULTS WITH A HISTORY OF INADEQUATE RESPONSE TO ORAL PREVENTIVE MEDICATIONS | No dispute reported | 06/30/2026 | 1228704796 |
| Principal investigator 1 | PFIZER INC. | $500.00 | 03/20/2025 | Non-covered Recipient Entity Dynamed Clinical Research LP dba DM Clinical Research | A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND TOLERABILITY OF RIMEGEPANT FOR THE PREVENTION OF MIGRAINE IN ADULTS WITH A HISTORY OF INADEQUATE RESPONSE TO ORAL PREVENTIVE MEDICATIONS | No dispute reported | 06/30/2026 | 1228704958 |
| Principal investigator 1 | PFIZER INC. | $2,418.63 | 03/20/2025 | Non-covered Recipient Entity Dynamed Clinical Research LP dba DM Clinical Research | A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND TOLERABILITY OF RIMEGEPANT FOR THE PREVENTION OF MIGRAINE IN ADULTS WITH A HISTORY OF INADEQUATE RESPONSE TO ORAL PREVENTIVE MEDICATIONS | No dispute reported | 06/30/2026 | 1228704960 |
| Principal investigator 1 | PFIZER INC. | $500.00 | 03/20/2025 | Non-covered Recipient Entity Dynamed Clinical Research LP dba DM Clinical Research | A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND TOLERABILITY OF RIMEGEPANT FOR THE PREVENTION OF MIGRAINE IN ADULTS WITH A HISTORY OF INADEQUATE RESPONSE TO ORAL PREVENTIVE MEDICATIONS | No dispute reported | 06/30/2026 | 1228704962 |
| Principal investigator 1 | PFIZER INC. | $500.00 | 03/20/2025 | Non-covered Recipient Entity Dynamed Clinical Research LP dba DM Clinical Research | A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE | No dispute reported | 06/30/2026 | 1228705006 |
| Principal investigator 1 | PFIZER INC. | $550.00 | 03/20/2025 | Non-covered Recipient Entity Dynamed Clinical Research LP dba DM Clinical Research | A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE | No dispute reported | 06/30/2026 | 1228705150 |
| Principal investigator 1 | PFIZER INC. | $500.00 | 03/20/2025 | Non-covered Recipient Entity Dynamed Clinical Research LP dba DM Clinical Research | A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE | No dispute reported | 06/30/2026 | 1228705158 |
| Principal investigator 1 | PFIZER INC. | $500.00 | 03/20/2025 | Non-covered Recipient Entity Dynamed Clinical Research LP dba DM Clinical Research | A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE | No dispute reported | 06/30/2026 | 1228705160 |
| Principal investigator 1 | PFIZER INC. | $250.00 | 03/20/2025 | Non-covered Recipient Entity Dynamed Clinical Research LP dba DM Clinical Research | A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE | No dispute reported | 06/30/2026 | 1228705290 |
| Principal investigator 1 | PFIZER INC. | $500.00 | 03/20/2025 | Non-covered Recipient Entity Dynamed Clinical Research LP dba DM Clinical Research | A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND TOLERABILITY OF RIMEGEPANT FOR THE PREVENTION OF MIGRAINE IN ADULTS WITH A HISTORY OF INADEQUATE RESPONSE TO ORAL PREVENTIVE MEDICATIONS | No dispute reported | 06/30/2026 | 1228705518 |
| Principal investigator 1 | PFIZER INC. | $550.00 | 03/20/2025 | Non-covered Recipient Entity Dynamed Clinical Research LP dba DM Clinical Research | A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND TOLERABILITY OF RIMEGEPANT FOR THE PREVENTION OF MIGRAINE IN ADULTS WITH A HISTORY OF INADEQUATE RESPONSE TO ORAL PREVENTIVE MEDICATIONS | No dispute reported | 06/30/2026 | 1228705520 |
| Principal investigator 1 | PFIZER INC. | $50,353.94 | 03/20/2025 | Non-covered Recipient Entity Dynamed Clinical Research LP | A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1228833333 |
| Principal investigator 1 | ModernaTX, Inc. | $8,000.38 | 03/19/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age | No dispute reported | 06/30/2026 | 1252992654 |
| Principal investigator 1 | PFIZER INC. | $189.80 | 03/10/2025 | Non-covered Recipient Entity DM Clinical ResearchCyfair | A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1228707483 |
| Principal investigator 1 | PFIZER INC. | $189.80 | 03/10/2025 | Non-covered Recipient Entity DM Clinical Research | A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1228827321 |
| Principal investigator 1 | ModernaTX, Inc. | $1,650.00 | 03/07/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age | No dispute reported | 06/30/2026 | 1252992784 |
| Principal investigator 1 | Bavarian Nordic A/S | $74.00 | 03/05/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | EBSI-CV-317-008 | No dispute reported | 06/30/2026 | 1250214080 |
| Principal investigator 1 | Bavarian Nordic A/S | $74.00 | 03/05/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | EBSI-CV-317-008 | No dispute reported | 06/30/2026 | 1250214180 |
| Principal investigator 1 | Bavarian Nordic A/S | $331.88 | 03/05/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | EBSI-CV-317-008 | No dispute reported | 06/30/2026 | 1250214182 |
| Principal investigator 1 | Bavarian Nordic A/S | $231.88 | 03/05/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | EBSI-CV-317-008 | No dispute reported | 06/30/2026 | 1250214184 |
| Principal investigator 1 | Bavarian Nordic A/S | $6,238.02 | 03/05/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | EBSI-CV-317-008 | No dispute reported | 06/30/2026 | 1250214216 |
| Principal investigator 1 | ModernaTX, Inc. | $1,130.00 | 03/05/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | Study of mRNA-1010 Seasonal Influenza Vaccine in Adults | No dispute reported | 06/30/2026 | 1252992386 |
| Principal investigator 1 | ModernaTX, Inc. | $1,130.00 | 03/05/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | Study of mRNA-1010 Seasonal Influenza Vaccine in Adults | No dispute reported | 06/30/2026 | 1252992516 |
| Principal investigator 1 | ModernaTX, Inc. | $2,250.00 | 03/05/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | Study of mRNA-1010 Seasonal Influenza Vaccine in Adults | No dispute reported | 06/30/2026 | 1252992518 |
| Principal investigator 1 | ModernaTX, Inc. | $950.04 | 03/05/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | Study of mRNA-1010 Seasonal Influenza Vaccine in Adults | No dispute reported | 06/30/2026 | 1252992794 |
| Principal investigator 1 | ModernaTX, Inc. | $14,585.41 | 03/05/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | Study of mRNA-1010 Seasonal Influenza Vaccine in Adults | No dispute reported | 06/30/2026 | 1252992796 |
| Principal investigator 1 | ModernaTX, Inc. | $1,300.00 | 03/05/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | Study of mRNA-1010 Seasonal Influenza Vaccine in Adults | No dispute reported | 06/30/2026 | 1252992798 |
| Principal investigator 1 | PFIZER INC. | $50.00 | 03/05/2025 | Non-covered Recipient Entity Dynamed Clinical Research LP | A PHASE 12 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1228833338 |
| Principal investigator 1 | PFIZER INC. | $5,057.57 | 03/04/2025 | Non-covered Recipient Entity Dynamed Clinical Research LP | A PHASE 12 RANDOMIZED DOUBLEBLIND TRIAL OF THE SAFETY AND IMMUNOGENICITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE IN ADULTS 18 YEARS OF AGE AND OLDER | No dispute reported | 06/30/2026 | 1228832809 |
| Principal investigator 1 | PFIZER INC. | $14,500.00 | 03/04/2025 | Non-covered Recipient Entity Dynamed Clinical Research LP | A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1228832858 |
| Principal investigator 1 | Bavarian Nordic A/S | $2,961.90 | 03/03/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | EBSI-CV-317-008 | No dispute reported | 06/30/2026 | 1250214230 |
| Principal investigator 1 | ModernaTX, Inc. | $1,143.13 | 03/03/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Study of mRNA-based Influenza and SARS-CoV-2 (COVID-19) Multi-component Vaccines in Healthy Adults | No dispute reported | 06/30/2026 | 1252992392 |
| Principal investigator 1 | ModernaTX, Inc. | $2,371.20 | 02/27/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253009742 |
| Principal investigator 1 | ModernaTX, Inc. | $7,080.00 | 02/27/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253009764 |
| Principal investigator 1 | PFIZER INC. | $3,246.76 | 02/26/2025 | Non-covered Recipient Entity Dynamed Clinical Research LP | A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS | No dispute reported | 06/30/2026 | 1228825808 |
| Principal investigator 1 | PFIZER INC. | $20,794.62 | 02/26/2025 | Non-covered Recipient Entity Dynamed Clinical Research LP | A PHASE 12 RANDOMIZED DOUBLEBLIND TRIAL OF THE SAFETY AND IMMUNOGENICITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE IN ADULTS 18 YEARS OF AGE AND OLDER | No dispute reported | 06/30/2026 | 1228825849 |
| Principal investigator 1 | PFIZER INC. | $65,620.20 | 02/25/2025 | Non-covered Recipient Entity Dynamed Clinical Research LP | A PHASE 12 RANDOMIZED DOUBLEBLIND TRIAL OF THE SAFETY AND IMMUNOGENICITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE IN ADULTS 18 YEARS OF AGE AND OLDER | No dispute reported | 06/30/2026 | 1228826331 |
| Principal investigator 1 | ModernaTX, Inc. | $3,000.00 | 02/24/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253009750 |
| Principal investigator 1 | Bavarian Nordic A/S | $74.00 | 02/21/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | EBSI-CV-317-008 | No dispute reported | 06/30/2026 | 1250214082 |
| Principal investigator 1 | Bavarian Nordic A/S | $271.63 | 02/21/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | EBSI-CV-317-008 | No dispute reported | 06/30/2026 | 1250214084 |
| Principal investigator 1 | Bavarian Nordic A/S | $74.00 | 02/21/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | EBSI-CV-317-008 | No dispute reported | 06/30/2026 | 1250214186 |
| Principal investigator 1 | Bavarian Nordic A/S | $231.88 | 02/21/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | EBSI-CV-317-008 | No dispute reported | 06/30/2026 | 1250214188 |
| Principal investigator 1 | Bavarian Nordic A/S | $483.63 | 02/21/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | EBSI-CV-317-008 | No dispute reported | 06/30/2026 | 1250214190 |
| Principal investigator 1 | Bavarian Nordic A/S | $271.63 | 02/21/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | EBSI-CV-317-008 | No dispute reported | 06/30/2026 | 1250214192 |
| Principal investigator 1 | Lexicon Pharmaceuticals, Inc. | $241.30 | 02/21/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | LX9211.1-204-DPN | No dispute reported | 06/30/2026 | 1248068085 |
| Principal investigator 1 | ModernaTX, Inc. | $4,091.62 | 02/21/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age | No dispute reported | 06/30/2026 | 1252992790 |
| Principal investigator 1 | ModernaTX, Inc. | $35,708.64 | 02/21/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Study to Investigate the Immunogenicity and Safety of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in High-risk Adults | No dispute reported | 06/30/2026 | 1252992842 |
| Principal investigator 1 | PFIZER INC. | $793.20 | 02/19/2025 | Non-covered Recipient Entity Dynamed Clinical Research LP dba DM Clinical Research | A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE | No dispute reported | 06/30/2026 | 1228704956 |
| Principal investigator 1 | PFIZER INC. | $100.00 | 02/19/2025 | Non-covered Recipient Entity Dynamed Clinical Research LP dba DM Clinical Research | A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE | No dispute reported | 06/30/2026 | 1228705010 |
| Principal investigator 1 | PFIZER INC. | $1,894.87 | 02/19/2025 | Non-covered Recipient Entity Dynamed Clinical Research LP dba DM Clinical Research | A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE | No dispute reported | 06/30/2026 | 1228705102 |
| Principal investigator 1 | PFIZER INC. | $5,110.66 | 02/19/2025 | Non-covered Recipient Entity Dynamed Clinical Research LP | A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS | No dispute reported | 06/30/2026 | 1228826408 |
| Principal investigator 1 | PFIZER INC. | $1,125.91 | 02/19/2025 | Non-covered Recipient Entity Dynamed Clinical Research LP | A PHASE 12 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1228827590 |
| Principal investigator 1 | ModernaTX, Inc. | $50.00 | 02/12/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age | No dispute reported | 06/30/2026 | 1252992508 |
| Principal investigator 1 | ModernaTX, Inc. | $4,372.50 | 02/12/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age | No dispute reported | 06/30/2026 | 1252992792 |
| Principal investigator 1 | PFIZER INC. | $811.69 | 02/12/2025 | Non-covered Recipient Entity Dynamed Clinical Research LP | A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS | No dispute reported | 06/30/2026 | 1228826322 |
| Principal investigator 1 | PFIZER INC. | $1,216.67 | 02/12/2025 | Non-covered Recipient Entity Dynamed Clinical Research LP | A PHASE 12 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1228827596 |
| Principal investigator 1 | PFIZER INC. | $447.85 | 02/08/2025 | Non-covered Recipient Entity Dynamed Clinical Research LP | A PHASE 12 RANDOMIZED DOUBLEBLIND TRIAL OF THE SAFETY AND IMMUNOGENICITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE IN ADULTS 18 YEARS OF AGE AND OLDER | No dispute reported | 06/30/2026 | 1228825804 |
| Recipient | SANOFI US SERVICES INC. | $323.11 | 02/08/2025 | Covered Recipient Physician | A Phase 2a/b, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of Subcutaneous Amlitelimab in Adult Patients With Nonresponsive Celiac Disease as an Adjunct to a Gluten-free Diet | No dispute reported | 06/30/2026 | 1226117366 |
| Recipient | SANOFI US SERVICES INC. | $398.62 | 02/08/2025 | Covered Recipient Physician | A Phase 2a/b, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of Subcutaneous Amlitelimab in Adult Patients With Nonresponsive Celiac Disease as an Adjunct to a Gluten-free Diet | No dispute reported | 06/30/2026 | 1226117373 |
| Recipient | SANOFI US SERVICES INC. | $630.54 | 02/08/2025 | Covered Recipient Physician | A Phase 2a/b, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of Subcutaneous Amlitelimab in Adult Patients With Nonresponsive Celiac Disease as an Adjunct to a Gluten-free Diet | No dispute reported | 06/30/2026 | 1226117378 |
| Recipient | SANOFI US SERVICES INC. | $69.00 | 02/08/2025 | Covered Recipient Physician | A Phase 2a/b, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of Subcutaneous Amlitelimab in Adult Patients With Nonresponsive Celiac Disease as an Adjunct to a Gluten-free Diet | No dispute reported | 06/30/2026 | 1226117403 |
| Recipient | SANOFI US SERVICES INC. | $69.00 | 02/08/2025 | Covered Recipient Physician | A Phase 2a/b, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of Subcutaneous Amlitelimab in Adult Patients With Nonresponsive Celiac Disease as an Adjunct to a Gluten-free Diet | No dispute reported | 06/30/2026 | 1226117409 |
| Recipient | SANOFI US SERVICES INC. | $74.50 | 02/08/2025 | Covered Recipient Physician | A Phase 2a/b, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of Subcutaneous Amlitelimab in Adult Patients With Nonresponsive Celiac Disease as an Adjunct to a Gluten-free Diet | No dispute reported | 06/30/2026 | 1226117415 |
| Principal investigator 1 | ModernaTX, Inc. | $15,000.00 | 02/07/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253009734 |
| Recipient | SANOFI US SERVICES INC. | $69.00 | 02/07/2025 | Covered Recipient Physician | A Phase 2a/b, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of Subcutaneous Amlitelimab in Adult Patients With Nonresponsive Celiac Disease as an Adjunct to a Gluten-free Diet | No dispute reported | 06/30/2026 | 1226117385 |
| Recipient | SANOFI US SERVICES INC. | $85.00 | 02/07/2025 | Covered Recipient Physician | A Phase 2a/b, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of Subcutaneous Amlitelimab in Adult Patients With Nonresponsive Celiac Disease as an Adjunct to a Gluten-free Diet | No dispute reported | 06/30/2026 | 1226117391 |
| Recipient | SANOFI US SERVICES INC. | $102.00 | 02/07/2025 | Covered Recipient Physician | A Phase 2a/b, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of Subcutaneous Amlitelimab in Adult Patients With Nonresponsive Celiac Disease as an Adjunct to a Gluten-free Diet | No dispute reported | 06/30/2026 | 1226117397 |
| Principal investigator 1 | ABBVIE INC. | $1,349.13 | 02/05/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | M14-465 - A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate | No dispute reported | 06/30/2026 | 1202445039 |
| Principal investigator 1 | Bavarian Nordic A/S | $74.00 | 02/05/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | EBSI-CV-317-008 | No dispute reported | 06/30/2026 | 1250214178 |
| Principal investigator 1 | Bavarian Nordic A/S | $331.88 | 02/05/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | EBSI-CV-317-008 | No dispute reported | 06/30/2026 | 1250214194 |
| Principal investigator 1 | Bavarian Nordic A/S | $231.88 | 02/05/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | EBSI-CV-317-008 | No dispute reported | 06/30/2026 | 1250214198 |
| Principal investigator 1 | ModernaTX, Inc. | $1,500.00 | 02/05/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Study to Evaluate the Safety and Immune Response of mRNA-1345, a Vaccine Targeting Respiratory Syncytial Virus (RSV), When Co-administered With a Fluzone HD, in Adults ?65 Years of Age | No dispute reported | 06/30/2026 | 1252992488 |
| Principal investigator 1 | ModernaTX, Inc. | $500.00 | 02/05/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Study to Evaluate the Safety and Immune Response of mRNA-1345, a Vaccine Targeting Respiratory Syncytial Virus (RSV), When Co-administered With a Fluzone HD, in Adults ?65 Years of Age | No dispute reported | 06/30/2026 | 1252992490 |
| Principal investigator 1 | ModernaTX, Inc. | $1,950.00 | 02/05/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Study to Evaluate the Safety and Immune Response of mRNA-1345, a Vaccine Targeting Respiratory Syncytial Virus (RSV), When Co-administered With a Fluzone HD, in Adults ?65 Years of Age | No dispute reported | 06/30/2026 | 1252992630 |
| Principal investigator 1 | ModernaTX, Inc. | $626.00 | 02/05/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Study to Evaluate the Safety and Immune Response of mRNA-1345, a Vaccine Targeting Respiratory Syncytial Virus (RSV), When Co-administered With a Fluzone HD, in Adults ?65 Years of Age | No dispute reported | 06/30/2026 | 1252992772 |
| Principal investigator 1 | PFIZER INC. | $150.00 | 02/05/2025 | Non-covered Recipient Entity Dynamed Clinical Research LP | A PHASE 12 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1228827582 |
| Principal investigator 1 | PFIZER INC. | $2,350.00 | 02/04/2025 | Non-covered Recipient Entity DM Clinical ResearchCyfair | A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1228707485 |
| Principal investigator 1 | PFIZER INC. | $726.10 | 02/04/2025 | Non-covered Recipient Entity DM Clinical ResearchCyfair | A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1228707670 |
| Principal investigator 1 | PFIZER INC. | $317.00 | 02/04/2025 | Non-covered Recipient Entity DM Clinical ResearchCyfair | A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1228707840 |
| Principal investigator 1 | PFIZER INC. | $317.00 | 02/04/2025 | Non-covered Recipient Entity DM Clinical Research | A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1228827859 |
| Principal investigator 1 | PFIZER INC. | $726.10 | 02/04/2025 | Non-covered Recipient Entity DM Clinical Research | A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1228828775 |
| Principal investigator 1 | Bavarian Nordic A/S | $74.00 | 02/03/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | EBSI-CV-317-008 | No dispute reported | 06/30/2026 | 1250214200 |
| Principal investigator 1 | Bavarian Nordic A/S | $231.88 | 02/03/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | EBSI-CV-317-008 | No dispute reported | 06/30/2026 | 1250214202 |
| Principal investigator 1 | ModernaTX, Inc. | $550.00 | 02/03/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age | No dispute reported | 06/30/2026 | 1252992506 |
| Principal investigator 1 | ModernaTX, Inc. | $2,858.88 | 02/03/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age | No dispute reported | 06/30/2026 | 1252992658 |
| Principal investigator 1 | ModernaTX, Inc. | $2,782.50 | 02/03/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age | No dispute reported | 06/30/2026 | 1252992664 |
| Principal investigator 1 | ModernaTX, Inc. | $500.00 | 02/03/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age | No dispute reported | 06/30/2026 | 1252992878 |
| Principal investigator 1 | Seqirus USA Inc | $1,019.00 | 02/03/2025 | Non-covered Recipient Entity Dynamed Clinical Research | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1185296608 |
| Principal investigator 1 | Seqirus USA Inc | $508.00 | 02/03/2025 | Non-covered Recipient Entity Dynamed Clinical Research | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1185296610 |
| Principal investigator 1 | Seqirus USA Inc | $1,019.00 | 02/03/2025 | Non-covered Recipient Entity Dynamed Clinical Research | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1185296618 |
| Principal investigator 1 | Seqirus USA Inc | $1,019.00 | 02/03/2025 | Non-covered Recipient Entity Dynamed Clinical Research | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1185296620 |
| Principal investigator 1 | Seqirus USA Inc | $508.00 | 02/03/2025 | Non-covered Recipient Entity Dynamed Clinical Research | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1185296622 |
| Principal investigator 1 | Seqirus USA Inc | $508.00 | 02/03/2025 | Non-covered Recipient Entity Dynamed Clinical Research | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1185296624 |
| Principal investigator 1 | Seqirus USA Inc | $508.00 | 02/03/2025 | Non-covered Recipient Entity Dynamed Clinical Research | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1185296626 |
| Principal investigator 1 | Seqirus USA Inc | $508.00 | 02/03/2025 | Non-covered Recipient Entity Dynamed Clinical Research | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1185296628 |
| Principal investigator 1 | Seqirus USA Inc | $508.00 | 02/03/2025 | Non-covered Recipient Entity Dynamed Clinical Research | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1185296630 |
| Principal investigator 1 | Seqirus USA Inc | $508.00 | 02/03/2025 | Non-covered Recipient Entity Dynamed Clinical Research | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1185296632 |
| Principal investigator 1 | Seqirus USA Inc | $508.00 | 02/03/2025 | Non-covered Recipient Entity Dynamed Clinical Research | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1185296634 |
| Principal investigator 1 | Seqirus USA Inc | $508.00 | 02/03/2025 | Non-covered Recipient Entity Dynamed Clinical Research | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1185296636 |
| Principal investigator 1 | Seqirus USA Inc | $508.00 | 02/03/2025 | Non-covered Recipient Entity Dynamed Clinical Research | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1185296640 |
| Principal investigator 1 | Seqirus USA Inc | $508.00 | 02/03/2025 | Non-covered Recipient Entity Dynamed Clinical Research | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1185296642 |
| Principal investigator 1 | Seqirus USA Inc | $508.00 | 02/03/2025 | Non-covered Recipient Entity Dynamed Clinical Research | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1185296644 |
| Principal investigator 1 | Seqirus USA Inc | $508.00 | 02/03/2025 | Non-covered Recipient Entity Dynamed Clinical Research | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1185296646 |
| Principal investigator 1 | Seqirus USA Inc | $508.00 | 02/03/2025 | Non-covered Recipient Entity Dynamed Clinical Research | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1185296648 |
| Principal investigator 1 | Seqirus USA Inc | $508.00 | 02/03/2025 | Non-covered Recipient Entity Dynamed Clinical Research | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1185296650 |
| Principal investigator 1 | Seqirus USA Inc | $508.00 | 02/03/2025 | Non-covered Recipient Entity Dynamed Clinical Research | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1185296652 |
| Principal investigator 1 | Seqirus USA Inc | $508.00 | 02/03/2025 | Non-covered Recipient Entity Dynamed Clinical Research | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1185296654 |
| Principal investigator 1 | Seqirus USA Inc | $508.00 | 02/03/2025 | Non-covered Recipient Entity Dynamed Clinical Research | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1185296656 |
| Principal investigator 1 | Seqirus USA Inc | $508.00 | 02/03/2025 | Non-covered Recipient Entity Dynamed Clinical Research | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1185296658 |
| Principal investigator 1 | Seqirus USA Inc | $508.00 | 02/03/2025 | Non-covered Recipient Entity Dynamed Clinical Research | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1185296660 |
| Principal investigator 1 | Seqirus USA Inc | $508.00 | 02/03/2025 | Non-covered Recipient Entity Dynamed Clinical Research | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1185296662 |
| Principal investigator 1 | Seqirus USA Inc | $1,019.00 | 02/03/2025 | Non-covered Recipient Entity Dynamed Clinical Research | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1185296688 |
| Principal investigator 1 | Seqirus USA Inc | $1,019.00 | 02/03/2025 | Non-covered Recipient Entity Dynamed Clinical Research | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1185296690 |
| Principal investigator 1 | Seqirus USA Inc | $1,019.00 | 02/03/2025 | Non-covered Recipient Entity Dynamed Clinical Research | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1185296692 |
| Principal investigator 1 | Seqirus USA Inc | $1,019.00 | 02/03/2025 | Non-covered Recipient Entity Dynamed Clinical Research | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1185296694 |
| Principal investigator 1 | Seqirus USA Inc | $1,019.00 | 02/03/2025 | Non-covered Recipient Entity Dynamed Clinical Research | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1185296696 |
| Principal investigator 1 | Seqirus USA Inc | $1,019.00 | 02/03/2025 | Non-covered Recipient Entity Dynamed Clinical Research | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1185296698 |
| Principal investigator 1 | Lexicon Pharmaceuticals, Inc. | $241.30 | 01/31/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | LX9211.1-204-DPN | No dispute reported | 06/30/2026 | 1248067159 |
| Principal investigator 1 | PFIZER INC. | $837.08 | 01/31/2025 | Non-covered Recipient Entity DM Clinical Research | A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1228814626 |
| Principal investigator 1 | PFIZER INC. | $981.24 | 01/31/2025 | Non-covered Recipient Entity DM Clinical Research | A PHASE 12 RANDOMIZED DOUBLEBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1228815363 |
| Principal investigator 1 | ModernaTX, Inc. | $4,499.04 | 01/29/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ?12 Years of Age to Prevent COVID-19 | No dispute reported | 06/30/2026 | 1252992738 |
| Principal investigator 1 | PFIZER INC. | $10,938.98 | 01/29/2025 | Non-covered Recipient Entity Dynamed Clinical Research LP | A PHASE 12 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1228832821 |
| Principal investigator 1 | PFIZER INC. | $20,506.00 | 01/28/2025 | Non-covered Recipient Entity Dynamed Clinical Research LP | A PHASE 12 RANDOMIZED DOUBLEBLIND TRIAL OF THE SAFETY AND IMMUNOGENICITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE IN ADULTS 18 YEARS OF AGE AND OLDER | No dispute reported | 06/30/2026 | 1228833026 |
| Principal investigator 1 | ModernaTX, Inc. | $2,371.20 | 01/27/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253009732 |
| Principal investigator 1 | ModernaTX, Inc. | $13,984.00 | 01/27/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253009736 |
| Principal investigator 1 | ModernaTX, Inc. | $10,450.00 | 01/27/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253009766 |
| Principal investigator 1 | PFIZER INC. | $887.77 | 01/25/2025 | Non-covered Recipient Entity Dynamed Clinical Research LP | A PHASE 12 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1228833076 |
| Principal investigator 1 | ModernaTX, Inc. | $34,778.65 | 01/24/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age | No dispute reported | 06/30/2026 | 1252992666 |
| Principal investigator 1 | Bavarian Nordic A/S | $231.88 | 01/22/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | EBSI-CV-317-008 | No dispute reported | 06/30/2026 | 1250214204 |
| Principal investigator 1 | Bavarian Nordic A/S | $74.00 | 01/22/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | EBSI-CV-317-008 | No dispute reported | 06/30/2026 | 1250214206 |
| Principal investigator 1 | ModernaTX, Inc. | $4,309.96 | 01/22/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Study of mRNA-1647 Cytomegalovirus Vaccine in Healthy Participants 9 to 15 Years of Age and Participants 16 to 25 Years of Age | No dispute reported | 06/30/2026 | 1252992494 |
| Principal investigator 1 | ModernaTX, Inc. | $6,094.90 | 01/22/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Study of mRNA-1647 Cytomegalovirus Vaccine in Healthy Participants 9 to 15 Years of Age and Participants 16 to 25 Years of Age | No dispute reported | 06/30/2026 | 1252992774 |
| Principal investigator 1 | PFIZER INC. | $8,271.22 | 01/22/2025 | Non-covered Recipient Entity Dynamed Clinical Research LP | A PHASE 12 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1228832612 |
| Principal investigator 1 | Seqirus USA Inc | $204.82 | 01/22/2025 | Non-covered Recipient Entity Dynamed Clinical Research | The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older | No dispute reported | 06/30/2026 | 1185296700 |
| Principal investigator 1 | ModernaTX, Inc. | $950.00 | 01/17/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age | No dispute reported | 06/30/2026 | 1252992782 |
| Principal investigator 1 | ModernaTX, Inc. | $546.56 | 01/17/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age | No dispute reported | 06/30/2026 | 1252992872 |
| Principal investigator 1 | PFIZER INC. | $16,305.35 | 01/15/2025 | Non-covered Recipient Entity Dynamed Clinical Research LP | A PHASE 12 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1228832472 |
| Principal investigator 1 | Lexicon Pharmaceuticals, Inc. | $3,064.70 | 01/14/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | LX9211.1-204-DPN | No dispute reported | 06/30/2026 | 1248067155 |
| Principal investigator 1 | Lexicon Pharmaceuticals, Inc. | $68.00 | 01/14/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | LX9211.1-204-DPN | No dispute reported | 06/30/2026 | 1248067157 |
| Principal investigator 1 | PFIZER INC. | $1,435.00 | 01/13/2025 | Non-covered Recipient Entity DM Clinical Research Cyfair | A PHASE 12 RANDOMIZED DOUBLEBLIND TRIAL OF THE SAFETY AND IMMUNOGENICITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE IN ADULTS 18 YEARS OF AGE AND OLDER | No dispute reported | 06/30/2026 | 1228827913 |
| Principal investigator 1 | Bavarian Nordic A/S | $2,610.00 | 01/10/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | EBSI-CV-317-008 | No dispute reported | 06/30/2026 | 1250214210 |
| Principal investigator 1 | ModernaTX, Inc. | $2,150.00 | 01/10/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Study of mRNA-based Influenza and SARS-CoV-2 (COVID-19) Multi-component Vaccines in Healthy Adults | No dispute reported | 06/30/2026 | 1252992520 |
| Principal investigator 1 | Amgen Inc. | $196,845.68 | 01/09/2025 | Non-covered Recipient Entity DM CLINICAL RESEARCH - CYFAIR CLINICAL RESEARCH CENTER | A Study to Evaluate the Efficacy, Safety & Tolerability of Maridebart Cafraglutide in Adults With T2DM | No dispute reported | 06/30/2026 | 1246640831 |
| Principal investigator 1 | Bavarian Nordic A/S | $1,802.00 | 01/08/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | EBSI-CV-317-008 | No dispute reported | 06/30/2026 | 1250214208 |
| Principal investigator 1 | Bavarian Nordic A/S | $300.00 | 01/08/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | EBSI-CV-317-008 | No dispute reported | 06/30/2026 | 1250214212 |
| Principal investigator 1 | Bavarian Nordic A/S | $650.00 | 01/08/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | EBSI-CV-317-008 | No dispute reported | 06/30/2026 | 1250214214 |
| Principal investigator 1 | PFIZER INC. | $1,435.00 | 01/06/2025 | Non-covered Recipient Entity DM Clinical Research Cyfair | A PHASE 12 RANDOMIZED DOUBLEBLIND TRIAL OF THE SAFETY AND IMMUNOGENICITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE IN ADULTS 18 YEARS OF AGE AND OLDER | No dispute reported | 06/30/2026 | 1228707666 |
| Principal investigator 1 | AstraZeneca UK Limited | $11,677.00 | 01/03/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Phase I-III Randomized Double blind Study to Evaluate the Safety and Neutralizing Activity of AZD5156-AZD3152 for Pre exposure Prophylaxis of COVID 19 in Participants with Conditions Causing Immune Impairment | No dispute reported | 06/30/2026 | 1185538382 |
| Principal investigator 1 | ModernaTX, Inc. | $9,158.67 | 01/03/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Study of mRNA-1647 Cytomegalovirus Vaccine in Healthy Participants 9 to 15 Years of Age and Participants 16 to 25 Years of Age | No dispute reported | 06/30/2026 | 1252992496 |
| Principal investigator 1 | ModernaTX, Inc. | $7,081.30 | 01/03/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Study to Investigate the Immunogenicity and Safety of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in High-risk Adults | No dispute reported | 06/30/2026 | 1252992612 |
| Principal investigator 1 | ModernaTX, Inc. | $150.00 | 01/03/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Study of mRNA-based Influenza and SARS-CoV-2 (COVID-19) Multi-component Vaccines in Healthy Adults | No dispute reported | 06/30/2026 | 1252992670 |
| Principal investigator 1 | ModernaTX, Inc. | $3,568.57 | 01/03/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | A Study of mRNA-based Influenza and SARS-CoV-2 (COVID-19) Multi-component Vaccines in Healthy Adults | No dispute reported | 06/30/2026 | 1252992802 |
| Principal investigator 1 | ABBVIE INC. | $1,656.93 | 01/02/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | M14-465 - A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate | No dispute reported | 06/30/2026 | 1202434958 |
| Principal investigator 1 | ABBVIE INC. | $355.50 | 01/02/2025 | Non-covered Recipient Entity DYNAMED CLINICAL RESEARCH LP | M14-465 - A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate | No dispute reported | 06/30/2026 | 1202434961 |
| Principal investigator 1 | PFIZER INC. | $46.38 | 01/01/2025 | Non-covered Recipient Entity Dynamed Clinical Research LP dba DM Clinical Research | A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE | No dispute reported | 06/30/2026 | 1228704798 |
| Principal investigator 1 | PFIZER INC. | $247.00 | 01/01/2025 | Non-covered Recipient Entity Dynamed Clinical Research LP dba DM Clinical Research | A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE | No dispute reported | 06/30/2026 | 1228704802 |
| Principal investigator 1 | PFIZER INC. | $1,300.77 | 01/01/2025 | Non-covered Recipient Entity Dynamed Clinical Research LP dba DM Clinical Research | A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE | No dispute reported | 06/30/2026 | 1228705004 |
| Principal investigator 1 | PFIZER INC. | $1,500.00 | 01/01/2025 | Non-covered Recipient Entity Dynamed Clinical Research LP | A PHASE 12 RANDOMIZED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA COVID19 VACCINE AND A RECOMBINANT INFLUENZA VACCINE ADMINISTERED AS A SINGLE INJECTION IN HEALTHY ADULTS 50 YEARS OF AGE OR OLDER | No dispute reported | 06/30/2026 | 1228832467 |
| Principal investigator 1 | PFIZER INC. | $22,963.90 | 01/01/2025 | Non-covered Recipient Entity Dynamed Clinical Research LP | A PHASE 12 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED VACCINE CANDIDATES AGAINST INFLUENZA AND COVID19 IN HEALTHY INDIVIDUALS | No dispute reported | 06/30/2026 | 1228832816 |